Amoxicillin - Drug Information - UpToDate

10/10/23, 15:48 Amoxicillin: Drug information - UpToDate
Access Lexicomp Online for additional drug information, tools, and databases.
Copyright 1978-2023 Lexicomp, Inc. All rights reserved.
Contributor Disclosures
(For additional information see "Amoxicillin: Patient drug information" and see "Amoxicillin: Pediatric drug
information")
For abbreviations, symbols, and age group definitions used in Lexicomp ( show table)
Brand Names: Canada

AG-Amoxicillin; APO-Amoxi; APO-Amoxi Sugar Free [DSC]; Auro-Amoxicillin; DOM-
Amoxicillin; JAMP-Amoxicillin; Novamoxin; PMS-Amoxicillin; Polymox; PRO Amox-500; PRO-
Amox-250
Pharmacologic Category
Antibiotic, Penicillin
Dosing: Adult
Usual dosage range: Oral: 500 mg to 1 g every 8 to 12 hours.

Collapse All
Actinomycosis 
Actinomycosis (alternative agent) (off-label use):
Note: For initial therapy of mild infection or step-down therapy following

parenteral treatment of severe infection (Ref).
Oral: 500 mg 3 to 4 times daily or 1 g 3 times daily (Ref); higher doses of 4 to 6

g/day in divided doses have been utilized in case reports (Ref). Optimal duration
is uncertain; some experts suggest total durations of 2 to 6 months for mild
infection and 6 to 12 months for severe or extensive infection (Ref).
Anthrax 
Anthrax (alternative agent [susceptible strains only]) (off-label use):
Note: Consult public health officials for event-specific recommendations. A high

index of suspicion for emergent beta-lactam resistance during therapy is
https://www.uptodate.com/contents/amoxicillin-drug-information?search=amoxicilina&source=panel_search_result&selectedTitle=1~148&usage… 1/47
warranted (Ref).
Inhalational (postexposure prophylaxis): Oral: 1 g every 8 hours (Ref); duration

depends on anthrax vaccine status and series completion, age, immune status,
and pregnancy/breastfeeding status. For those who have not previously
received anthrax vaccine, duration ranges from 42 to 60 days (Ref). Some
experts favor longer durations of prophylaxis (eg, total of 3 to 4 months) for
patients who are immunocompromised or remain unvaccinated (Ref).
Note: Anthrax vaccine should also be administered to exposed individuals

(Ref).
Cutaneous, without systemic involvement, treatment: Oral: 1 g every 8 hours;

duration is 7 to 10 days after naturally acquired infection and 60 days following
biological weapon-related event. Note: Treat patients with extensive edema or
cutaneous lesions of the head or neck with a parenteral regimen recommended
for systemic involvement (Ref).
Bronchiectasis 
Bronchiectasis:
Treatment of pulmonary exacerbations in patients without beta-lactamase-positive

H. influenzae or Pseudomonas aeruginosa: Oral: 500 mg 3 times daily (Ref) or 1 g
3 times daily (Ref) for up to 14 days (Ref).
Prevention of pulmonary exacerbations: Note: Reserve for patients with ≥3

exacerbations per year who are not colonized with P. aeruginosa and not
candidates for long-term macrolide therapy (Ref).
Oral: 500 mg twice daily; dosing based on expert opinion (Ref).
Cervical infection in pregnancy due to Chlamydia trachomatis 
Cervical infection in pregnancy due to Chlamydia trachomatis (alternative

agent) (off-label use):
Note: Reserve for patients who are pregnant who cannot use preferred agents
(Ref)
Oral: 500 mg 3 times daily for 7 days with test of cure ≥4 weeks after treatment
(Ref).
Endocarditis, prophylaxis 
Endocarditis, prophylaxis before invasive dental procedures (off-label use):

Oral: 2 g 30 to 60 minutes before procedure; if inadvertently not given prior to the
procedure, may be administered up to 2 hours after the procedure. Note: Reserve
for select situations (cardiac condition with the highest risk of adverse endocarditis
outcomes and procedure likely to result in bacteremia with an organism that can
cause endocarditis) (Ref).
Helicobacter pylori eradication 
Helicobacter pylori eradication: Oral:
Clarithromycin triple regimen: Amoxicillin 1 g twice daily in combination with

clarithromycin 500 mg twice daily, plus a standard-dose or double-dose proton
pump inhibitor; continue regimen for 14 days. Note: Avoid use in patients with
risk factors for macrolide resistance (eg, prior macrolide exposure or local
clarithromycin resistance rates ≥15%, which is assumed in the United States)
(Ref).
Concomitant regimen: Amoxicillin 1 g twice daily in combination with

clarithromycin 500 mg twice daily, either metronidazole or tinidazole 500 mg
twice daily, plus a standard-dose proton pump inhibitor twice daily; continue
regimen for 10 to 14 days (Ref).
Sequential regimen (alternative regimen): Amoxicillin 1 g twice daily plus a

standard-dose proton pump inhibitor twice daily for 5 to 7 days; followed by
clarithromycin 500 mg twice daily, either metronidazole or tinidazole 500 mg
twice daily, plus a standard-dose proton pump inhibitor twice daily for 5 to 7
days; some experts prefer the 10-day regimen due to the lack of data showing
superiority of the 14-day sequential regimen in North America (Ref).
Hybrid regimen (alternative regimen): Amoxicillin 1 g twice daily, plus a standard-

dose proton pump inhibitor twice daily for 7 days; followed by amoxicillin 1 g
twice daily, clarithromycin 500 mg twice daily, either metronidazole or tinidazole
500 mg twice daily, plus a standard-dose proton pump inhibitor twice daily for 7
days (Ref).
Levofloxacin triple regimen (salvage regimen): Amoxicillin 750 mg 3 times daily in

combination with a double-dose proton pump inhibitor twice daily plus
levofloxacin 500 mg once daily; continue regimen for 14 days (Ref).
High-dose dual therapy (alternative salvage regimen): Amoxicillin 750 mg 4 times

daily or 1 g 3 times daily; in combination with a double-dose proton pump
inhibitor twice daily for 14 days (Ref).
Lyme disease 
Lyme disease (Borrelia spp. infection) (off-label use):
Erythema migrans: Oral: 500 mg 3 times daily for 14 days (Ref).
Carditis (initial therapy for mild disease [first-degree atrioventricular block with PR
interval <300 msec] or step-down therapy after initial parenteral treatment for more
severe disease once PR interval <300 msec): Oral: 500 mg 3 times daily for 14 to 21
days (Ref).
Arthritis without neurologic involvement: Oral: 500 mg 3 times daily for 28 days
(Ref).
Otitis media, acute 
Otitis media, acute (alternative agent):
Note: Some experts recommend amoxicillin/clavulanate over amoxicillin alone

due to the frequency of otopathogens that produce beta-lactamases (eg, H.
influenzae, Moraxella catarrhalis) (Ref).
Oral: 500 mg every 8 hours or 875 mg every 12 hours (Ref). Some experts use 1
g every 8 hours for patients at high risk of severe infection or resistant
Streptococcus pneumoniae. Duration is 5 to 7 days for mild to moderate infection
and 10 days for severe infection (Ref).
Periodontitis, severe, plaque-associated 
Periodontitis, severe, plaque-associated (off-label use): Oral: 500 mg every 8

hours in combination with metronidazole for 14 days or until clinical resolution,
whichever is longer; use in addition to periodontal debridement (Ref).
Pneumococcal prophylaxis in patients at high risk 
Pneumococcal prophylaxis in patients at high risk (off-label use):
Note: For select patients at high risk (eg, patients with functional or anatomic
asplenia, sickle cell disease, or allogeneic hematopoietic cell transplant
recipients with chronic graft-vs-host disease or hypogammaglobulinemia) (Ref).
Oral: Dose not well-defined: 500 mg twice daily (Ref); based on

recommendations in pediatric patients >5 years of age, may consider 250 mg
twice daily (Ref). Some experts recommend 250 mg once daily. Duration varies
based on patient-specific factors (Ref).
Pneumonia, community-acquired 
Pneumonia, community-acquired:
Note: For empiric therapy in outpatients without comorbidities or risk factors

for antibiotic-resistant pathogens or oral step-down therapy following initial
parenteral therapy (Ref).
Oral: 1 g 3 times daily (Ref); for initial empiric therapy, some experts prefer use
of amoxicillin in combination with an antibiotic that targets atypical pathogens
(Ref). Duration is for a minimum of 5 days; patients should be clinically stable
with normal vital signs before therapy is discontinued (Ref).
Prosthetic joint infection, chronic suppression 
Prosthetic joint infection, chronic suppression (off-label use):
Note: For infection caused by beta-hemolytic streptococci, penicillin-susceptible

Enterococcus spp., or Cutibacterium spp. (following pathogen-specific IV therapy
in patients undergoing 1-stage exchange or debridement with retention of
prosthesis) (Ref).
Oral: 500 mg 3 times daily (Ref); duration depends on patient-specific factors

(Ref).
Rhinosinusitis, acute bacterial 
Rhinosinusitis, acute bacterial:
Note: In uncomplicated acute bacterial rhinosinusitis, initial observation and

symptom management without antibiotic therapy is appropriate in most
patients. Reserve antibiotic therapy for poor follow-up or lack of improvement
over the observation period (Ref). For initial therapy of nonsevere infection in
patients without risk factors for pneumococcal resistance or poor outcome (eg,
≥65 years of age, recent hospitalization or antibiotic use, multiple comorbidities,
high endemic resistance) (Ref).
Oral: 500 mg every 8 hours or 875 mg every 12 hours for 5 to 7 days (Ref).
Skin and soft tissue infection 
Skin and soft tissue infection:
Erysipelas, treatment of mild infection or step-down therapy after initial parenteral

therapy:
Oral: 500 mg 3 times daily or 875 mg twice daily; total duration is 5 days,
with extension to 14 days for slow response, severe infection, or
immunosuppression (Ref).
Erysipeloid (localized cutaneous Erysipelothrix rhusiopathiae infection):
Oral: 500 mg 3 times daily for 5 to 10 days (Ref).
Streptococcal pharyngitis 
Streptococcal pharyngitis (group A): Oral: 500 mg twice daily or 1 g once daily for
10 days (Ref).
Urinary tract infection 
Urinary tract infection:
Note: Not recommended for empiric therapy given decreased efficacy

compared to first-line agents and high prevalence of resistance (Ref).
Asymptomatic bacteriuria (≥105 CFU per mL) in pregnancy (eg, group B

Streptococcus): Oral: 500 mg every 8 hours or 875 mg every 12 hours for 4 to 7
days (Ref).
Cystitis, acute uncomplicated or acute simple cystitis (infection limited to the bladder
without signs/symptoms of upper tract, prostate, or systemic infection) due to
Enterococcus spp.: Oral: 500 mg every 8 hours or 875 mg every 12 hours for 5
days (Ref).
Dosage adjustment for concomitant therapy: Significant drug interactions exist,

requiring dose/frequency adjustment or avoidance. Consult drug interactions
database for more information.
Dosing: Kidney Impairment: Adult
The renal dosing recommendations are based upon the best available evidence and
clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF;
Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
Altered kidney function:
Oral:
Amoxicillin Dose Adjustments in Kidney Impairment
If the normal recommended If the normal recommended If the normal

GFR (mL/minute) dose is 250 to 500 mg every dose is 875 mg to 1 g every recommended dose is 1 g
8 hoursa 12 hoursb every 8 hoursb,c
No dosage adjustment No dosage adjustment No dosage adjustment

≥30
necessary necessary necessary
10 to 30 250 to 500 mg every 12 hours 500 mg every 12 hours 1 g every 12 hours
250 to 500 mg every 12 to 24

<10 500 mg every 12 to 24 hours 500 mg every 12 hours
hours
Hemodialysis,
250 to 500 mg every 12 to 24
intermittent (thrice 500 mg every 12 to 24 hours 500 mg every 12 hours
hours
weekly)d
Peritoneal dialysis 250 to 500 mg every 12 hours 500 mg every 12 hours 500 mg every 12 hours
aGolightly 2013; Szeto 2017; manufacturer's labeling; expert opinion

b
Expert opinion
cKeller 2015
d
Dialyzable (30% to 47% with low flux filters [Davies 1988; Francke 1979]). If utilizing a 24-hour dosing interval,
administer dose after dialysis or give an additional dose after dialysis on dialysis days.
Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.
Dosing: Older Adult

Refer to adult dosing.
Dosing: Pediatric
(For additional information see "Amoxicillin: Pediatric drug information")
General dosing:
Infants, Children, and Adolescents:
Standard-dose regimen: Oral: 40 to 45 mg/kg/day in divided doses every 8

hours; maximum dose: 500 mg/dose (Ref).
High-dose regimen: 80 to 90 mg/kg/day divided every 12 hours; a maximum

dose has not been established; however, some experts suggest a maximum
daily dose of 4,000 mg/day (Ref).
Expand All
Anthrax 
Endocarditis, prophylaxis before invasive dental procedures 
Exit-site or tunnel infection, peritoneal dialysis catheter 
Helicobacter pylori eradication 
Lyme disease 
Osteoarticular infection, acute 
Otitis media, acute 
Peritonitis, prophylaxis for peritoneal dialysis patients requiring invasive 

dental procedures
Pneumonia, community-acquired 
Pneumococcal infection prophylaxis for anatomic or functional asplenia 
Rhinosinusitis, acute bacterial; uncomplicated 
Streptococcus, group A; pharyngitis/tonsillitis 
Urinary tract infection, prophylaxis 
Urinary tract infection, treatment 
Dosage adjustment for concomitant therapy: Significant drug interactions exist,

requiring dose/frequency adjustment or avoidance. Consult drug interactions
database for more information.
Dosing: Kidney Impairment: Pediatric
There are no dosage adjustments provided in the manufacturer's labeling; however,

the following guidelines have been used by some clinicians (Ref): Oral:
Infants, Children, and Adolescents:
Mild to moderate infection: Dosing based on 25 to 50 mg/kg/day divided every

8 hours:
GFR >30 mL/minute/1.73 m2: No adjustment required.
GFR 10 to 29 mL/minute/1.73 m2: 8 to 20 mg/kg/dose every 12 hours.
GFR <10 mL/minute/1.73 m2: 8 to 20 mg/kg/dose every 24 hours.
Hemodialysis: Moderately dialyzable (20% to 50%); ~30% removed by 3-

hour hemodialysis: 8 to 20 mg/kg/dose every 24 hours; give after dialysis.
Peritoneal dialysis: 8 to 20 mg/kg/dose every 24 hours.
Severe infection (high dose): Dosing based on 80 to 90 mg/kg/day divided

every 12 hours:
GFR >30 mL/minute/1.73 m2: No adjustment required.
GFR 10 to 29 mL/minute/1.73 m2: 20 mg/kg/dose every 12 hours; do not

use the 875 mg tablet.
GFR <10 mL/minute/1.73 m2: 20 mg/kg/dose every 24 hours; do not use

the 875 mg tablet.
Hemodialysis: Moderately dialyzable (20% to 50%); ~30% removed by 3-

hour hemodialysis: 20 mg/kg/dose every 24 hours; give after dialysis.
Peritoneal dialysis: 20 mg/kg/dose every 24 hours.
Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.
Adverse Reactions (Significant): Considerations

Expand All
Antibiotic-associated (non–Clostridioides difficile) diarrhea 
Clostridioides difficile diarrhea 
Hypersensitivity and immunologic reactions (immediate and delayed) 
Adverse Reactions
The following adverse drug reactions and incidences are derived from product labeling
unless otherwise specified.
1% to 10%: Gastrointestinal: Diarrhea, nausea, vomiting
Postmarketing:
Dermatologic: Acute generalized exanthematous pustulosis (Choon 2018),

erythema multiforme, erythematous maculopapular rash (Koosakulchai 2021),
exfoliative dermatitis, pruritus, skin rash (Katoh 2021), Stevens-Johnson syndrome
(Yang 2020), toxic epidermal necrolysis (Yang 2020), urticaria (Koosakulchai 2021)
Gastrointestinal: Clostridioides difficile colitis, Clostridioides difficile-associated

diarrhea, hemorrhagic colitis, melanoglossia, mucocutaneous candidiasis, staining
of tooth
Genitourinary: Crystalluria
Hematologic & oncologic: Agranulocytosis, anemia, eosinophilia, hemolytic

anemia (Rossi 2010), immune thrombocytopenia, leukopenia, neutropenia (Curtis
2017), thrombocytopenia
Hepatic: Cholestatic hepatitis (Kim 2011), cholestatic jaundice, hepatitis (acute

cytolytic), increased serum alanine aminotransferase (Kim 2011), increased serum
aspartate aminotransferase (Kim 2011)
Hypersensitivity: Anaphylactic shock, anaphylaxis (Piotin 2021), angioedema

(Koosakulchai 2021), drug reaction with eosinophilia and systemic symptoms (De
La Cruz 2021), hypersensitivity angiitis (Garcia-Porrua 1999), nonimmune
anaphylaxis, serum sickness-like reaction (Mohsenzadeh 2020)
Nervous system: Agitation, anxiety, aseptic meningitis, behavioral changes,

confusion, dizziness, hyperactive behavior (reversible), insomnia, seizure
Contraindications
Serious hypersensitivity to amoxicillin (eg, anaphylaxis, Stevens-Johnson syndrome) or

to other beta-lactams, or any component of the formulation
Canadian labeling: Additional contraindications (not in US labeling): Infectious

mononucleosis (suspected or confirmed)
https://www.uptodate.com/contents/amoxicillin-drug-information?search=amoxicilina&source=panel_search_result&selectedTitle=1~148&usag… 10/47
Warnings/Precautions
Concerns related to adverse effects:
• Superinfection: Prolonged use may result in fungal or bacterial superinfection.
Disease-related concerns:
• Infectious mononucleosis: A high percentage of patients with infectious

mononucleosis develop an erythematous rash during amoxicillin therapy; avoid
use in these patients.
• Renal impairment: Use with caution in patients with renal impairment; dosage
adjustment recommended.
Dosage form specific issues:
• Benzyl alcohol and derivatives: Some dosage forms may contain sodium
benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;
large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a
potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome”
consists of metabolic acidosis, respiratory distress, gasping respirations, CNS
dysfunction (including convulsions, intracranial hemorrhage), hypotension, and
cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that
benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use
dosage forms containing benzyl alcohol derivative with caution in neonates. See
manufacturer's labeling.
• Chewable tablets: May contain phenylalanine; see manufacturer's labeling.
Dosage Forms: US
Excipient information presented when available (limited, particularly for generics); consult
specific product labeling.
Capsule, Oral:
Generic: 250 mg, 500 mg
Suspension Reconstituted, Oral:
Generic: 125 mg/5 mL (80 mL, 100 mL, 150 mL); 200 mg/5 mL (50 mL, 75 mL, 100
mL); 250 mg/5 mL (80 mL, 100 mL, 150 mL); 400 mg/5 mL (50 mL, 75 mL, 100 mL)
Tablet, Oral:

Tablet Chewable, Oral:
Generic Equivalent Available: US

Yes
Pricing: US
Capsules (Amoxicillin Oral)
250 mg (per each): $0.13 - $0.25
500 mg (per each): $0.19 - $0.39
Chewable (Amoxicillin Oral)
125 mg (per each): $0.37
250 mg (per each): $0.74
Suspension (reconstituted) (Amoxicillin Oral)
125 mg/5 mL (per mL): $0.04
200 mg/5 mL (per mL): $0.09
250 mg/5 mL (per mL): $0.06
400 mg/5 mL (per mL): $0.10
Tablets (Amoxicillin Oral)
500 mg (per each): $0.50
875 mg (per each): $0.87
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is

provided as reference price only. A range is provided when more than one manufacturer's
AWP price is available and uses the low and high price reported by the manufacturers to
determine the range. The pricing data should be used for benchmarking purposes only,
and as such should not be used alone to set or adjudicate any prices for reimbursement or
purchasing functions or considered to be an exact price for a single product and/or
manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether
express or implied, and assumes no liability with respect to accuracy of price or price range
data published in its solutions. In no event shall Medi-Span be liable for special, indirect,
incidental, or consequential damages arising from use of price or price range data. Pricing
data is updated monthly.
Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult
specific product labeling. [DSC] = Discontinued product
Capsule, Oral:
Polymox: 250 mg, 500 mg
Suspension Reconstituted, Oral:
Polymox: 125 mg/5 mL (150 mL); 250 mg/5 mL (150 mL)
Generic: 125 mg/5 mL (100 mL, 150 mL); 250 mg/5 mL (75 mL, 100 mL, 150 mL)
Tablet Chewable, Oral:
Generic: 125 mg [DSC], 250 mg
Administration: Adult
Oral: Administer around-the-clock to promote less variation in peak and trough serum
levels.
Suspension: Shake well before use; may be mixed with formula, milk, fruit juice, water,
ginger ale, or cold drinks; administer dose immediately after mixing.
Administration: Pediatric
Oral: May be administered on an empty or full stomach; may be mixed with small amount
of formula, milk, cold drink, or juice; administer dose immediately after mixing; shake
suspension well before use.
Use: Labeled Indications
Ear, nose, and throat infections (pharyngitis/tonsillitis, acute otitis media):

Treatment of infection due to beta-lactamase-negative Streptococcus spp. (alpha- and
beta-hemolytic isolates only), Streptococcus pneumoniae, Staphylococcus spp., or
Haemophilus influenzae.
Helicobacter pylori eradication: Eradication of H. pylori to reduce the risk of duodenal

ulcer recurrence as a component of combination therapy in patients with active or 1-
year history of duodenal ulcer disease.
Lower respiratory tract infections (including pneumonia): Treatment of infection of

the lower respiratory tract due to beta-lactamase-negative Streptococcus spp. (alpha-
and beta-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae.
Rhinosinusitis, acute bacterial: Treatment of infection due to beta-lactamase-

negative Streptococcus spp. (alpha- and beta-hemolytic isolates only), S. pneumoniae,
Staphylococcus spp., or H. influenzae.
Skin and soft tissue infection: Treatment of infection of the skin and soft tissue due
to beta-lactamase-negative Streptococcus spp. (alpha- and beta-hemolytic strains only),
Staphylococcus spp., or Escherichia coli.
Urinary tract infection: Treatment of infection of the genitourinary tract due to beta-
lactamase-negative E. coli, Proteus mirabilis, or Enterococcus faecalis.
Use: Off-Label: Adult
Actinomycosis; Anthrax; Cervical infection in pregnancy due to Chlamydia trachomatis;

Endocarditis, prophylaxis; Lyme disease (Borrelia spp. infection); Periodontitis, severe,
plaque-associated; Pneumococcal prophylaxis in patients at high risk; Prosthetic joint
infection, chronic suppression
Medication Safety Issues

Expand All
Sound-alike/look-alike issues: 
International issues: 
Metabolism/Transport Effects
Substrate of OAT1/3
Drug Interactions
(For additional information: Launch drug interactions program)
Note: Interacting drugs may not be individually listed below if they are part of a group
interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a
complete list of drug interactions by individual drug name and detailed management
recommendations, use the Lexicomp drug interactions program by clicking on the “Launch
drug interactions program” link above.
Acemetacin: May increase the serum concentration of Penicillins. Risk C: Monitor

therapy
Allopurinol: May enhance the potential for allergic or hypersensitivity reactions to

Amoxicillin. Risk C: Monitor therapy
Aminoglycosides: Penicillins may decrease the serum concentration of

Aminoglycosides. Primarily associated with extended spectrum penicillins, and
patients with renal dysfunction. Risk C: Monitor therapy
Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.
Management: Bacillus clausii should be taken in between antibiotic doses during
concomitant therapy. Risk D: Consider therapy modification
BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical).
Risk X: Avoid combination
BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG
Vaccine (Immunization). Risk C: Monitor therapy
Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.
Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and
within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid
combination
Dichlorphenamide: Penicillins may enhance the hypokalemic effect of

Dichlorphenamide. Risk C: Monitor therapy
Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics. Risk X:
Avoid combination
Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal
Microbiota (Live) (Rectal). Risk X: Avoid combination
Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics

may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-
L1, and -CTLA4 Therapies). Risk C: Monitor therapy
Khat: May decrease the serum concentration of Amoxicillin. Management: Consider

administering amoxicillin before, or 2 hours after, khat chewing to avoid reductions in
amoxicillin bioavailability. Risk D: Consider therapy modification
Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of

Lactobacillus and Estriol. Risk C: Monitor therapy
Methotrexate: Penicillins may increase the serum concentration of Methotrexate. Risk

C: Monitor therapy
Mycophenolate: Penicillins may decrease serum concentrations of the active

metabolite(s) of Mycophenolate. This effect appears to be the result of impaired
enterohepatic recirculation. Risk C: Monitor therapy
Probenecid: May increase the serum concentration of Penicillins. Risk C: Monitor therapy
Sodium Benzoate: Penicillins may diminish the therapeutic effect of Sodium Benzoate.
Risk C: Monitor therapy
Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium

Picosulfate. Management: Consider using an alternative product for bowel cleansing
prior to a colonoscopy in patients who have recently used or are concurrently using an
antibiotic. Risk D: Consider therapy modification
Tetracyclines: May diminish the therapeutic effect of Penicillins. Risk C: Monitor therapy
Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine.
Only the live attenuated Ty21a strain is affected. Management: Avoid use of live
attenuated typhoid vaccine (Ty21a) in patients being treated with systemic
antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics
and avoid starting antibiotics within 3 days of last vaccine dose. Risk D: Consider therapy
modification
Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect
of Vitamin K Antagonists. Risk C: Monitor therapy
Pregnancy Considerations
Amoxicillin crosses the placenta (Muller 2009; Zareba-Szczudlik 2017). Maternal serum
concentrations are significantly greater than the umbilical cord, placenta, and amniotic
fluid concentrations when amoxicillin is administered orally prior to delivery (Buckingham
1975; Zareba-Szczudlik 2017).
Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of oral

amoxicillin may be altered. Renal clearance is increased in the second and third trimester
compared to postpartum values. In addition, oral absorption is decreased during labor.
Maternal adipose tissue and the presence of anemia may influence maternal serum and
amniotic fluid concentrations. Although minimum inhibitory concentrations can be
reached, higher oral doses (or a parenteral antibiotic) may be needed based on the specific
maternal infection or if treating an infection of the fetus and/or placenta (Andrew 2007;
Buckingham 1975; Zareba-Szczudlik 2017).
As a class, penicillin antibiotics are widely used in pregnant patients. Based on available
data, penicillin antibiotics are generally considered compatible for use during pregnancy
(Ailes 2016; Bookstaver 2015; Crider 2009; Damkier 2019; Lamont 2014; Muanda 2017a;
Muanda 2017b).
Amoxicillin may be used for the management of Bacillus anthracis in pregnant patients
when penicillin susceptibility is documented. Maternal infection with B. anthracis may cause
preterm labor, fetal infection, fetal distress, or fetal loss. Maternal death may also occur.
Amoxicillin is an alternative agent for the treatment of cutaneous anthrax without systemic
involvement and for the postexposure prophylaxis of B. anthracis during pregnancy. The
dose and duration of amoxicillin therapy in pregnant and postpartum patients is the same
as in nonpregnant adults. Adjustments in dose for pregnancy are not recommended until
additional pharmacokinetic data become available (Meaney-Delman 2014).
Untreated chlamydial disease can cause pelvic inflammatory disease, ectopic pregnancy,
and infertility. In addition, treatment of maternal disease usually prevents transmission to
the neonate during birth. Due to concerns of chlamydia persistence following exposure to
penicillin class antibiotics, amoxicillin is an alternative antibiotic for the treatment of
chlamydial infections in pregnancy (CDC [Workowski 2021]).
Amoxicillin is used for the treatment of Lyme disease. Vertical transmission from mother to
fetus is not well documented; it is unclear if infection increases the risk of adverse
pregnancy outcomes. When treatment for Lyme disease in pregnancy is needed, the
indications and dosing of amoxicillin are the same as in nonpregnant patients
(IDSA/AAN/ACR [Lantos 2021]; Lambert 2020; SOGC [Smith 2020]).
Untreated urinary tract infections (UTIs) during pregnancy are associated with an increased
risk of developing pyelonephritis, low birth weight, and preterm labor. Amoxicillin may be
an option for the treatment of UTI during pregnancy (de Rossi 2020; IDSA [Nicolle 2019]).
Amoxicillin is used in the management of H. pylori eradication. H. pylori is associated with

hyperemesis gravidarum and may be linked to other adverse maternal and fetal outcomes.
Treatment in patients with mild or no symptoms is generally delayed until after delivery;
however, amoxicillin may be considered as part of a treatment regimen when otherwise
appropriate (Cardaropoli 2014; Nguyen 2019; Zhan 2019).
Amoxicillin can also be used in the management of preterm prelabor rupture of

membranes (PROM); treatment with antibiotics is used to prolong pregnancy and decrease
maternal and newborn infections (ACOG 217 2020). Amoxicillin may also be used in certain
situations prior to vaginal delivery in patients at high risk for endocarditis (ACOG 199 2018).
Amoxicillin is considered compatible for the treatment airway diseases in pregnant patients
(ERS/TSANZ [Middleton 2020]).
Breastfeeding Considerations
Amoxicillin is present in breast milk (Kafetzis 1981).
Information related to the presence of amoxicillin in breast milk is available from 6

mothers given oral amoxicillin 1,000 mg on the third day postpartum. The mean peak
maternal serum concentration (15.6 mcg/mL) occurred at 2 hours after the dose. The
mean peak milk concentration occurred 4 to 5 hours after the dose and was 0.9
mcg/mL (range: 0.68 to 1.3 mcg/mL) (Kafetzis 1981).
Self-limiting diarrhea, rash, and somnolence have been reported in nursing infants
exposed to amoxicillin (Benyamini 2005; Goldstein 2009; Ito 1993); the manufacturer
warns of the potential for allergic sensitization in the infant. In general, antibiotics that
are present in breast milk may cause non-dose-related modification of bowel flora.
Monitor infants for GI disturbances, such as thrush or diarrhea (WHO 2002).
Although the manufacturer recommends that caution be exercised when

administering amoxicillin to breastfeeding patients, amoxicillin is considered
compatible with breastfeeding when used in usual recommended doses (WHO 2002).
Amoxicillin may be used to treat mastitis in breastfeeding patients. The treatment of

mastitis with antibiotics is generally not considered unless symptoms do not improve
with conservative management or the patient is acutely ill. When antibiotics are
clinically indicated for treatment, amoxicillin is one of the suggested therapies for
gram-negative organisms (WHO 2000).
Recommendations for using amoxicillin for the treatment of B. anthracis in

breastfeeding patients are the same as in pregnancy. Exposure to anthrax is not
considered a contraindication to breastfeeding. However, if there are active cutaneous
lesions on the breast, contact with the infant should be avoided and feeding from the
affected breast should not occur until >48 hours of appropriate antibiotic therapy
(Meaney-Delman 2014).
Dietary Considerations
Some products may contain phenylalanine.
Monitoring Parameters
With prolonged therapy, monitor renal, hepatic, and hematologic function periodically;
assess patient at beginning and throughout therapy for infection; monitor for signs of
anaphylaxis during first dose
Mechanism of Action
Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding
proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan
synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually
lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein
hydrolases) while cell wall assembly is arrested.
Pharmacokinetics (Adult Data Unless Noted)
Absorption: Oral: Rapid with or without food; delayed absorption may be seen in some
neonates and infants <60 days of age (Mir 2020).
Distribution: Readily into liver, lungs, prostate, muscle, middle ear effusions, maxillary
sinus secretions, bone, gallbladder, bile, and ascitic and synovial fluids; poor
cerebrospinal fluid penetration (except when meninges are inflamed).
Vd:
Neonates, including preterm (GA: 25 to 42 weeks; PNA: ≤9 days): 0.65 ± 0.13

L/kg (Pullen 2006).
Infants ≥3 months of age and children ≤5 years of age: 1.44 ± 0.37 L/kg
(Canafax 1998).
Protein binding: ~20%.
Bioavailability: Oral suspension: Neonates (GA: 37 to 43 weeks; PNA: 6 to 12 days): 75%

(range: 60% to 101%) (Lönnerholm 1982).
Half-life elimination:
Preterm and term neonates (GA: 25 to 42 weeks; PNA: ≤9 days): 5.2 ± 1.9 hours
(Pullen 2006).
Adults: 61.3 minutes.
Time to peak:
Preterm and term neonates (PNA: <5 days): Oral suspension: ~4 hours (Cohen
1975; Weingartner 1977); reported mean range: 2 to 6 hours (Keij 2019).
Adults: Capsule, oral suspension: 1 to 2 hours; chewable tablet: 1 hour.
Excretion: Urine (60% as unchanged drug); lower in neonates (Cohen 1975;

Weingartner 1977).
Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)
Anti-infective considerations:
Parameters associated with efficacy:
Time dependent; associated with time free drug concentration (fT) > minimum
inhibitory concentration, goal: ≥40% to 50% (bactericidal) (Andes 1998; Craig
1996; Craig 1998; Gustafsson 2001).
Expected drug exposure in normal renal function:
Infants ≥3 months of age and children ≤4 years of age, Cmax (peak):
15 mg/kg/dose 3 times daily, steady state: 7.9 ± 3.5 mg/L

(Fonseca 2003).
25 mg/kg/dose twice daily, steady state: 10.6 ± 5.1 mg/L (Fonseca

2003).
Adults, Cmax (peak):
125 mg, single dose (125 mg per 5 mL suspension): 1.5 to 3 mg/L.
250 mg, single dose (capsule or 250 mg per 5 mL suspension): 3.5

to 5 mg/L.
400 mg, single dose (chewable tablet): 5.18 ± 1.64 mg/L.
400 mg, single dose (400 mg per 5 mL suspension): 5.92 ± 1.62

mg/L.
500 mg, single dose: 5.5 to 7.5 mg/L.
875 mg, single dose: 13.8 ± 4.1 mg/L.
Postantibiotic effect:
H. influenzae: <1 hour; S. pneumoniae: 0.3 to 5.8 hours; viridans streptococci:

0.7 to 2 hours (Davies 2000; Dubois 2000; Lee 2000).
Brand Names: International

Find brand name(s) by country (for United States and Canada see separate Brand Names sections)
 Enter a Country or Country Code

International Brand Names by Country 
For country code abbreviations ( show table)
(AE) United Arab Emirates: Amoxidin | Amoxil | Amoxipen | Amoxycillin | Amoxydar | Danoxillin
| E mox | Flemoxin | Glomox | Hiconcil | Hipen | Hymox | Ibiamox | Julphamox | Moxilen |
Neomox | Omacillin | Ospamox | Penamox | Princimox | Ranoxyl | Remox | Ultramox; (AR)
Argentina: Almorsan | Amox-g | Amox-g duo | Amoxi duo mar | Amoxi Gno | Amoxi mar |
Amoxibiot | Amoxibiot forte | Amoxicilina | Amoxicilina drawer | Amoxicilina duo fecofar |
Amoxicilina fecofar | Amoxicilina lacefa | Amoxicilina lemax | Amoxicilina medipharma |
Amoxicilina puntanos | Amoxicilina richet | Amoxicilina richet duo | Amoxicilina sant gall friburg
| Amoxicilina shabba | Amoxicilina vannier | Amoxicina | Amoxicler | Amoxidal | Amoxidal duo
| Amoxifarma | Amoxigrand | Amoxipenil | Amoxipoten | Amoxitenk | Amoxol | Amoxol duo |
Ardine | Atrival | Biolabsa | Biolabsa duo | Biotamoxal | Bioxilina | Clofamox | Darzitil | Darzitil
duo | Darzitil plus | Dunox | Fabamox | Fada amoxicilina | Fullcilina | Fullcilina duo | Grinsil |
Larocilin | Mixcilin | Moxitral | Nobactam | Oximar | Ralipen | Trifamox | Xalotina; (AT) Austria:
Amoxicillin 1a pharma | Amoxicillin hexal | Amoxicillin ratiopharm | Amoxihexal | Amoxilan |
Amoxistad | Clamoxyl | Eramox | Ospamox; (AU) Australia: Alphamox | Amiloxyn | Amohexal |
Amoxicillin | Amoxil | Amoxil duo | Amoxycillin | Amoxycillin an | Amoxycillin generichealth |
Amoxycillin ps | Amoxycillin ranbaxy | Amoxycillin-dp | Apo amoxycillin | Bgramin | Cilamox |
Fisamox | Genrx amoxycillin | Ibiamox | Maxamox | Moxacin | Noumed amoxicillin | Ranmoxy
| Yomax; (BD) Bangladesh: Aldalin | Ambeexin | Amocap | Amocil | Amocin | Amolin | Amotid |
Amotid f | Amox | Amoxapen | Amoxicap | Amoxicillin | Amoxicillin e | Amoxicon | Amoxil |
Amoxilin | Amoxima | Amoxin | Amoxipan | Amoxisyrup | Amoxon | Antif | Apimox | Apoxy |
Aristomox | Avlomox | Bactamox | Bitoxil | Bpmox | Brodamox | Cemoxin | Chemoxilin |
Cidamox | Clamox | Demox | Demoxil | Dopen | E mox | Emoxil | Fimoxyl | Flamoxin |
Gemoxyl | Genamox | Hectamox | Hi mox | Hiconcil | Hymoxyl | J mox | Jamoxil | Kamoxicillin
| Kamoxy | Loxyl | Mimox | Moci | Monamox | Mox | Moxa | Moxacil | Moxapen | Moxatid |
Moxicillin | Moxico | Moxilin | Moxin | Moxitid | Moxyvan | Mumox | Mymoxcil | Navamox |
Neomox | Neucil | Oclomox | Orgamox | Orixyl | Pamoxil | Pemox | Penmox | Pentamox |
Pharmoxyl | Primox | Promox | Q-mox | Remamox | Remoxil | Remoxin | Remoxyl | Roxyl | S-
amoxy | Sapox | Seemaxyl | Servimox | Simox | Sinamox | Sk mox | Skymoxin | Stamox | Tycil
| Tymox | Tymoxil | Ultramox | Ultrapen | Unimox | Versamox | Xemox | Zimoxyl | Ziskamox;
(BE) Belgium: Amocilline | Amoxi | Amoxicillin ab | Amoxicilline apotex | Amoxicilline bexal |
Amoxicilline eg | Amoxicilline Eurogenerics | Amoxicilline merck-generics | Amoxicilline sandoz
| Amoxicilline teva generics belgium | Amoxycaps | Amoxypen | Bactimed | Clamoxyl |
Clamoxyl-Gsk | Docamoxici | Flemoxin | Hiconcil | Moxaline | Moxitop; (BF) Burkina Faso: Amoxi
denk | Amoxicilline | Amoxicilline sandoz | Amoxicilline ubigen | Amoxicilline winthrop |
Amoxirex | Bactox | Clamoxyl | Hiconcil | Imox | Linmox | Ospamox | Penamox | Philco Amoxy
| Ranoxyl; (BG) Bulgaria: Amopen | Medospamox | Ospamox | Ranoxyl | Upsamox; (BR) Brazil:
Amox-ems | Amoxadene | Amoxi-ped | Amoxibel | Amoxibron | Amoxicap | Amoxicilina |
Amoxidil | Amoxifar | Amoxil | Amoxil bd | Amoximed | Amoxina | Amoxipen | Amoxitan |
Amplal | Amplamox | Ariproxina | Atak | Axepen | Bimoxin | Camoxin | Cibramox | Cilimox |
Duzimicin | Farmoxil | Furp amoxicilina | Germoxil | Hiconcil | Hincomox | Ibamoxil | Iquego
amoxicilina | Licilon | Lifamox | Medxil | Moxiplus | Nemoxil | Neo moxilin | Novocilin | Ocylin
| Penvicilin | Pharmox | Polibac | Polimoxil | Sinot | Syfmox | Trimox | Ultramox | Uni amox |
Uniao amoxicilina | Velamox; (CH) Switzerland: Amoxi | Amoxi-basan | Amoxicillin 1a pharma |
Amoxicillin actavis | Amoxicillin cimex | Amoxicillin HelvePharm | Amoxicillin sandoz |
Amoxicillin spirig hc | Amoxicillin-biochemie | Amoxicilline axapharm | Amoxicilline sandoz |
Amoxicilline streuli | Azillin | Clamoxyl | Flemoxin | Penimox | Spectroxyl | Supramox; (CI) Côte
d'Ivoire: Agram | Amitron | Amodex | Amokod | Amoxal | Amoxi denk | Amoxicap | Amoxicillin
| Amoxicillin creacil | Amoxicilline | Amoxicilline bristol myers | Amoxicilline ubigen |
Amoxicilline winthrop | Amoxil | Amoxyn | Apo-amoxi | Bactox | Bristamox | Linmox | Lyamox
| Medomox | Novamox | Ospamox | Penamox | Pneumoccid | Polymoxyl | Pulmoxyl | Ranoxyl
| Theomox | Umoxil | Zamocilline; (CL) Chile: Abiolex | Abiolex duo | Amobiotic | Amoval |
Amoxicilina | Amoxipenil | Novamox | Optamox | Solomoxy | Unimox; (CN) China: A ke lin | A
mo jun | A mo xian | Amoxicillin | Amoxy | Amoxycillin | Flemoxin | Jiang bi lin | Lu tai ling |
Mai lin guang | Mo sa | Penamox | Ri ao | Xin da bei ning | Ya bao li ke | Yi sa lin | Zai lin; (CO)
Colombia: Adbiotin | Akrimoxy | Aldrimox | Amicil | Amoxal | Amoxen | Amoxicilina |
Amoxicilina bcn | Amoxicilina mk | Amoxidal | Amoxil | Amoxipen | Amoxtrix | Ampitrex |
Ampliex | Amprex | Bristamox | Faramox | Infemox | Moxacin | Neogram | Orvimox |
Ospamox | Servamox | Solomoxy | Tramotal | Trifamox | Tripsopen | Vonamocylin |
Weidermicina | Zakmar | Zamox; (CZ) Czech Republic: Apo amoxi | Ospamox; (DE) Germany:
Amagesan | Amoxi | Amoxi 1a pharma | Amoxi abz | Amoxi basf | Amoxi CT | Amoxi diolan |
Amoxi hefa | Amoxi hp | Amoxi saar | Amoxibeta | Amoxibeta T | Amoxicillin | Amoxicillin aristo
| Amoxicillin billix | Amoxicillin denk | Amoxicillin dura | Amoxicillin Heumann | Amoxicillin
micro labs | Amoxidoc | Amoxihexal | Amoxillat | Amoximerck | Amoxypen | Byk amoxicillin |
Dignoamoxicillin | Dura ax | Easymox | Espa Moxin | Infectomox | Infectomycin | Jephoxin |
Jutamox | Ospamox | Phamoxi | Sigamopen | Zamocillin; (DO) Dominican Republic: Acimox |
Aliveg | Amicil | Amitron | Amolix | Amotran | Amoval | Amoxicilina | Amoxicilina cinfa |
Amoxicilina lam | Amoxidal | Amoxidin | Amoxifur | Amoxil | Amoxmer | Atenac | Bactamox |
Baykid amoxicilina | Binox | Bioxil | Cipamox | Dicilina | Eupen | Grunamox | Inamox | Infemox
| Ipoxilina | Linamox | Luframoxil | Magnacyl | Meramox | Modexil | Mopen | Mox | Moxilac |
Moxilin | Moxiline | Orbimox | Ospamox | Raudopen | Sumox | Sumox duo | Tracyl | Xilibron;
(EC) Ecuador: Acromox | Amobiotic | Amoval | Amox | Amoxgran | Amoxicher | Amoxicilina |
Amoxicilina la sante | Amoxil | Amoxipen t | Amoxistar | Amoxital | Avamox | Baselmox |
Bristamox | Chenamox | Duomox | Ecumox | Grunamox | Julphamox | Libramox | Moxylin |
Neomox | Nifamox | Odontocilina | Orquiamox | Ospamox | Oxipen | Proxidal duo | Servamox
| Uosomox; (EE) Estonia: Amocileks | Amopen | Amoxicillin | Amoxicillin sandoz | Amoxycillin |
Bactox | Eramox | Gonoform | Hiconcil | Moxilen | Ospamox | Penalta | Upsamox; (EG) Egypt:
Alemox | Amoxicid | Amoxicillin | Amoxicillin stada | Amoxil | Amoxycillin | Aramox | Biomox |
Delpedox | E mox | Epcimox | Farconcil | Flemoxin | Hicillin | Hiconcil | Ibiamox | Moxacil |
Moxipen | Neomoxibact | Organomox | Ospamox | Rivamox | Unimox; (ES) Spain: Actimoxi |
Agerpen | Alfida | Amitron | Amoxaren | Amoxi gobens | Amoxibacter | Amoxicilina alter |
Amoxicilina aristo | Amoxicilina belmac | Amoxicilina bohm | Amoxicilina cinfa | Amoxicilina
cuve | Amoxicilina davur | Amoxicilina esteve | Amoxicilina juventus | Amoxicilina kern pharma
| Amoxicilina mundogen | Amoxicilina normon | Amoxicilina sandoz | Amoxidel | Apamox |
Ardine | Borbalan | Britamox | Bronco tonic | Clamoxyl | Co amoxin | Combitora | Dobriciclin |
Hosboral | Remisan | Salvapen | Suamoxil | Tolodina; (ET) Ethiopia: Amocin | Amoxapen |
Amoxi denk | Amoxicillin | Amoxid | Amoxil | Amyn | Asmox | Julphamox | Medomox | Moxipil
| Rivamox; (FI) Finland: Amorion | Amoxicillin Generics | Amoxicillin mip pharma | Amoxin |
Amoxipen | Clamox | Imacillin | Penalta; (FR) France: Amodex | Amophar | Amoxicilline |
Amoxicilline almus | Amoxicilline alter | Amoxicilline arrow | Amoxicilline biogaran |
Amoxicilline cristers | Amoxicilline hexal | Amoxicilline irex | Amoxicilline ivax | Amoxicilline
Merck | Amoxicilline ranbaxy | Amoxicilline ratiopharm | Amoxicilline rpg | Amoxicilline sandoz
| Amoxicilline teva | Amoxicilline zydus | Bactox | Bristamox | Clamoxyl | Flemoxine | Gramidil
| Hiconcil; (GB) United Kingdom: Amix | Amoram | Amoxicillin | Amoxident | Amoxidin | Amoxil
| Amoxycillin | Amoxycillin almus | Amoxycillin arrow | Amoxycillin berk | Amoxycillin cox |
Amoxycillin kent | Amoxycillin sandoz | Amoxydent | Amoxymed | Amrit | Galenamox |

Respillin | Rimoxallin | Zoxycil; (GH) Ghana: Permoxyl; (GR) Greece: Amospes | Amoxil |
Amoximycin | Amoxycillin | Aproxal | Flemoxin | Izoltil | Ospamox | Paradroxil | Triodanin; (HK)
Hong Kong: Amocap | Amolin | Amon-s | Amox | Amoxa | Amoxapen | Amoxicap | Amoxicillin
| Amoxigran | Amoxil | Amoxitab | Amoxon-g | Amoxon-p | Amoxon-s | Amoxon-w |
Amoxycillin | Amyn | Aroxin | Beamoxy | Edamox | Euromox | Hamoxillin | Hiconcil | Moxarin |
Moxcin | Moxen | Moxilen | Moxipen | Moxlin | Neomox | Ospamox | Panmox | Promox |
Ranoxyl | Reichamox | Setmoxil | Sinfung | Unicil | Unimox | Vidacillin | Vixmin | Zoramix-f;
(HR) Croatia: Almacin | Amoksicilin | Amoksicilin Belupo | Amoxil | Ospamox | Ospamox bid;
(HU) Hungary: Amoclen | Amogal | Amoxicillin bril | Duomox | Humamoxin | Ospamox; (ID)
Indonesia: Abamox | Amobiotic | Amox | Amoxicillin | Amoxil | Amoxillin | Amoxipen |
Amoxsan | Amoxycillin | Arcamox | Berlimox | Broadamox | Bufamoxy | Dexymox | Etamox |
Flemoxin | Hiconcil | Holimox | Inamox | Intermoxil | Medimox | Mexylin | Moxlin | Novamox |
Novax | Opimox | Ospamox | Pehamoxil | Penmox | Polymox | Rindamox | Robamox |
Servamox | Silamox | Sirimox | Supramox | Widecillin | Yusimox | Zemoxil; (IE) Ireland:
Amoxicillin | Amoxil | Clonamox | Galenamox | Geramox | Oramox | Pinamox | Rimoxallin; (IL)
Israel: Amoxi | Hiconcil | Moxypen | Moxyvit; (IN) India: A-mox | Acemox | Admoxin | Allmox |
Almox | Alphamox | Amocin | Amodryn | Amodux | Amotex | Amotid | Amox | Amoxi |
Amoxicillin | Amoxil | Amoxinga | Amoxipen | Amoxivan | Amoxy | Amoxybid | Amoxycillin |
Amoxygull | Amoxylin | Amoxysain | Amoxytop | Amurol | Amx | Amyn | Angemox | Antimox |
Aristomox | Arpimox | Atmox | Axn | Bactomox | Baromox | Bemox | Bemoxy | Benimox |
Betmox | Bigmox | Biomox | Biomoxil | Bitamox | Blismox | Blumox | Caremox | Cipmox |
Comoxyl | Cremox | Damoxy | Danemox | Delamin | Dentomox | Dicimox | Dynamox |
Edomox | Efimox | Efmox | Elmox | Epoxin | Erox | Esimox | Euphomox | Finemox | Flemoxin |
Galmox | Genmox | Germox | Glamoxin | Gutenmox | Healmox | Hemox | Hexamox | Hipen |
Hipen-a | Hipen-p | Hycimox | Hykil | Idimox | Ifimox | Imox | Infemox | Iphamox | Jetmox |
Kamoxyl | Lamoxy | Larixin | Libamox | Linmox | Loxyn | Lupimox | Medimox | Menmox |
Mentox-p | Merimox | Metamox | Mokcan | Mopen | Mormox | Mox | Mox kid | Mox-sg |
Moxcee | Moxcem | Moxene | Moxgard | Moxibact | Moxica | Moxicap | Moxiday | Moxikem |
Moxileb | Moxilin | Moxilink | Moxilion | Moxilup | Moximet | Moximon | Moxinta | Moxipal |
Moxisar | Moxitas | Moxley | Moxmed | Moxvid | Moxway | Moxxil | Moxybiotic | Moxyco |
Moxydil | Moxylar | Moxylife | Moxylite | Moxyzen | Mymox | Natamox | Nepomox |
Neumoxes | Nodimox | Nomox | Novamox | O moxy | Octamox | Olymox | Omox | Optimox |
Osomox | Pd mox | Pedimox | Pedmox | Peermox | Penom | Pexomox | Phenoxyl | Polymox |
Pranmox | Pressmox | Pulmoxyl | Puremox | R-mox | Radimox | Ranoxyl | Raymox | Rekmox |
Rizmox | Romexyl | Ronemox | Roscillin-amx | Sinmox | Sirimox | Softmox | Stalmox | Sumox |
Sunimox | Suzimox | Swimox | Symoxyl | Synamox | Threomox | Tormoxin | Toxi | Tram |
Trimox | Trimox ketone | Twicyl | Unilox | Unimox | Value mox | Vemox | Vermox | Warcilin |
Weloxy | Womox | Wymox | Xytid | Z-mox | Zamox | Zovax | Zox | Zycillin; (IT) Italy: Alfamox |
Amoflux | Amosol | Amox | Amoxicillina | Amoxicillina doc | Amoxicillina eg | Amoxicillina hex |
Amoxicillina jet | Amoxicillina sandoz | Amoxicillina zentiva | Amoxillin | Amoxina | Erremox |
Hydramox | Ibiamox | Isimoxin | Mopen | Moxiren | Neo ampiplus | Neotetranase | Oralmox |
Pamocil | Sintopen | Sintoplus | Velamox | Zimox; (JO) Jordan: Amoxapen | Amoxibel | Amoxil |
Amoxydar | Hiconcil | Hymox | Julphamox | Moxepharm | Moxilen | Moxiram | Ospamox |
Penamox | Ultramox; (JP) Japan: Amolin | Amopenixin | Amopicillin | Amopicillin taiyo |
Amosepacin | Amox | Amoxicillin | Amoxycillin | Amoxycillin amel | Amoxycillin fujimoto |
Amoxycillin hexal | Amoxycillin merck | Amoxycillin showa | Amoxycillin taiyo | Amoxycillin
tatumi kagaku | Amoxycillin towa | Anemolin | Apitart | Chitacillin | Clamoxyl | Delacillin |
Efpenix | Hiconcil | Himinomax | Niramitin | Pasetocin | Rimosin | Sawacillin | Sawamezin |
Seokicillin | Seokicillin choseido | Unicillin | Widecillin; (KE) Kenya: Alimox | Ambioxy ds | Amoxi
denk | Amoxicap | Amoxicillin | Amoxigen | Amoxigran | Amoxil | Amoxin | Amoxmark | Amyn
| Asmox | Biomox | Brumox | Camox | Conamox | Elymox | Farconcil | Gestamox | Imox |
Kamox | Kemoxyl | Labmox | Lemoxipen | Medomox | Miloxy | Moxacil | Moxacil forte |
Moxileb | Moxper | Neomox | Nesmox | Omacillin | Ospamox | Penamox | Promox | Pulmoxyl
| Rivamox | Septimox | Tunamox 250 dt; (KR) Korea, Republic of: A mox | A-cillin | Amocipen |
Amonex | Amox | Amox apen | Amoxapen | Amoxicare | Amoxicillin | Amoxicillin donga |
Amoxicillin samsung | Amoxis | Amxilline | Ckdamoxicillin | Gomcillin | Huons amoxicillin | Jw
amoxicillin | Kymoxin | Moxillin | Pamoxin | Pharma amoxicillin | Umoxen; (KW) Kuwait: Amoxil
| Glomox | Hiconcil | Hymox | Julphamox | Neomox | Omacillin | Ospamox | Remox |
Ultramox; (LB) Lebanon: Amodex | Amoxicillin | Amoxicilline | Amoxidrex | Amoxil | Amoxycillin
| Cipamox | E mox | Flemoxin | Gramidil | Hiconcil | Ibiamox | Julphamox | Moxilen | Ospamox
| Penamox | Reichamox | Zamocilline; (LT) Lithuania: Amocilex | Amoclen | Amopen | Amoxil |
Amoxycillin | Apo amoxi | Azillin | Bactox | Flemoxin | Hiconcil | Moxypen | Ospamox | Pan
amoxycillin; (LU) Luxembourg: Amoxi | Amoxicilline Eurogenerics | Amoxicilline sandoz |
Amoxihexal | Amoxypen | Clamoxyl | Flemoxin | Gramidil | Hiconcil | Moxaline | Novabritine;
(LV) Latvia: Amocilex | Amoclen | Amopen | Amoxil | Amoxycillin | Apo amoxi | Bactox |
Clamoxyl | Flemoxin | Hiconcil | Lamoxy | Moxilen | Moxypen | Mymox | Ospamox | Upsamox
| Winpen; (MA) Morocco: A-gram | Alfamox | Amodex | Amoxicilline | Amoxil | Apo-amoxi |
Aximycine | Bactamox | Bactox | Biomox | Cipamox | Clamox | Clamoxyl | Dispamox | Hiconcil
| Neomox | Ospamox | Penamox | Phamox | Pneumoccid | Servamox | Starmox | Streptocid;
(MX) Mexico: Acimox | Acroxil | Acroxil. | Amicil | Amiglan | Amobay | Amoxdar | Amoxicilina |
Amoxicilina g.i | Amoxicilina gi | Amoxicilina gi ser | Amoxicilina keyer | Amoxifur | Amoxil |
Amoxil 12 h | Amoxinovag | Amoxisol | Amoxivet | Ampicel | Ampliron | Amsaxilina | Ardine |
Armoxin | Betabiot | Bimoxan | Biovicam | Brenoxil | Brenoxil s | Clifen | Deniren | Dimopen |
Doxamil | Examolin | Flemoxon | Genobiotic moxi | Gimalxina | Grunicina | Hidramox |
Libiotex | Limoxin | Lorexil-m | Lumox | MicroMox | Mocimed | Moxicilina | Moxiclina | Moxlin
| Moxpharma | Ormocyn | Ormocyn t 5 | Pamoxab | Penamox | Penamox 12h | Penticlox |
Polymox | Servamox | Solciclina | Vandix | Vizimox | Xalyn-or | Xiprocan; (MY) Malaysia: Amolin
| Amoxicap | Amoxicillin | Amoxigran | Amoxil | Amoxilin | Amoxilla | Amoxitab | Amoxy |
Amoxycillin | Amoxycillin Pharmaniaga | Beamoxy | Betamox | Hamoxillin | Ifimox | Moxilen |
Moxipen | Ospamox | Ranoxyl | Setmoxil | Symoxyl | Synamox | Z mox | Zamoxil; (NG) Nigeria:
Acimox | Alamox | Amonex | Amoxapan | Amoxicillin marcolivia | Amoxil | Amoxynova |
Andersons amoxycillin | Annmox | Avromox | Betamoxin | Chimexbon amoxicillin | Cikamox |
Cimoxil | Dramoxicillin | Dramoxilin | Emmox | Fleming | Floximox | Grafclav | Hanbet
amoxicillin | Healmoxy | Ipcamox | Jawamox | Kenneth amoxicillin | Kinglion amoxicillin |
Krismox | Maryclantin | Miramox | Namox | Nemoxil | Noxil | Rainbow amoxicillin | Ricnos
amoxicillin | Vamoxil | Xtramox | Zimamox | Zimox; (NL) Netherlands: Amoxicilline |
Amoxicilline flx | Amoxicilline Merck | Amoxicilline ratiopharm | Amoxicilline sandoz |
Amoxicilline sandoz disper | Flemoxin; (NO) Norway: Amimox | Amoxicillin | Amoxicillin accord |
Amoxicillin sandoz | Amoxillin | Bremide | Imacillin | Imaxi; (NZ) New Zealand: Alphamox |
Amoxicillin actavis | Amoxil | Amoxycillin | Apo-amoxi | Moxlin | Noumed amoxicillin |
Ospamox; (OM) Oman: Omacillin; (PE) Peru: Alcevan | Amoval | Amoxi c | Amoxibiotech |
Amoxicilina | Amoxicilina trifarma | Amoxicilina uqp | Amoxiclin | Amoxiclin cl | Amoxidal duo |
Amoxidin | Amoxidin 7 | Amoxil | Amoxil 12 h | Amoxilip | Amoxilip 500 | Amoximass |
Amoxioral | Amoxipen | Amyn | Apmox | Apo-amoxi | Bactiomax | Bioxdrin | Bristamox |
Bronco amoxidin nf | Clavoxilin | Clavutrim | Deltamox | Derinox | Grunamox | Julphamox |
Magnific | Magnimox | Med amox | Moxicel | Novamox | Novaxon | Odontomox | Orabiot |
Orabiot duo | Ospamox | Penamox | Pentrax | Pentrax duo | Ranoxyl | Rhamoxilina |
Solomoxy | Supermoxil | Supramoxil | Terbomox | Trifamox | Velamox | Zezhatos; (PH)

Philippines: Acumox | Altomox | Amelox | Amorex | Amoxicillin | Amoxicillin sandoz | Amoxil |
Amoxsteryl | Amoxtrex | Amoxycillin | Amusa | Arimox | Bactigent | Benedex | Betamox | Boie
amoxicillin | Bradoxil | Broadmetz | Brumox | Cartrimox | Chrisomox | Cilfam | Clearamox |
Coamoxin | Cycamil | Daisamox | Eleomox | Eppitrexil | Essenmox | Evimox | Exbropin | Gexcil
| Giacillin | Glamox | Globamox | Globapen | Gorgonio | Grumox | Harbimox | Harvimox |
Himox | Infeban | Jamox | Ladoxillin | Lewixin | Littmox | Macromox | Maelenoxyl | Maroxil |
Medimoxil | Medvox | Megamox | Moks | Montramox | Moxidre | Moxillin | Moxiped |
Moxydril | Moxylor | Neomox | Novamox | Nuevamox | Nuevamoxil | Optimox | Oramox |
Pathogram | Pediamox | Pemoxin | Penbiosyn | Pharmamox | Phecymox | Philamox | Polymox
| Primex | Promox | Richmox | Rielmox | Roddexil | Semoxicillin | Semoxil | Servimox | Spectra
| Stamox | Sumoxil | Supramox | Syncloxil | Telsimox | Teramoxyl | Termox | Trexil | Trigan |
Usa-amoxicillin | Valmox | Valzimox | Varolox | Vastamox | Vaxman | Vhellox | Vistrep |
Vomoxyn | Westfimox | Wyamox | Xazexy | Yugoxil | Zedroxyn | Zymoxyl; (PK) Pakistan:
Adamox | Amfast | Amocillin | Amoxascot | Amoxene | Amoxicap | Amoxidox | Amoxil |
Amoxillin | Amoxycillin | Amoxygen | Amoxylin | Amoxypen | Ampimox | Arcomox | Arpimox |
Axalyn | Blomox | Cekamox | Ciloxil | Cipamox | Climox | Concimox | Cosmox | Delmox |
Effimox | Elmox | Enmox | Epoxcil | Excellin | Fedroxil | Geomoxin | Glimox | Himoxin |
Hizemox | Ibiamox | Imcomox | Jaxcil | Kemyclox | Klox | Maxil | Mb mox | Medimox | Medixil
| Moxifil | Moxilium | Moxin | Moxypen | Novomox | Ocemox | Ospamox | Oximox | Pemoxin
| Penbro | Penmox | Penoxil | Polyxil | Princimox | Regumoxil | Selmox | Semocillin | Skymox |
Stamox | Supramox | Tabrocil | Ultramox | Werimox | Wilmox | Wisep | Wymox | Zeemox |
Zekatac | Zoxicillin; (PL) Poland: Amoclen | Amotaks | Amoxicilline | Amoxycillin | Duomox |
Grunamox | Hiconcil | Ospamox; (PR) Puerto Rico: Amoxicillin | Amoxil | Moxatag | Polymox |
Trimox | Wymox; (PT) Portugal: Amoxicilina | Amoxicilina tolife | Amoxil | Amplamox | Bodisan
| Cipamox | Clamoxyl | Dilaclan | Moxadent | Moxipen | Oraminax | Ospamox; (PY) Paraguay:
Acimox | Amoval | Amoval duo | Amoxicilina ahimsa | Amoxicilina bional | Amoxicilina caplin
point | Amoxicilina cellofarm | Amoxicilina dallas | Amoxicilina eurofarma | Amoxicilina
eximfarma | Amoxicilina genfar | Amoxicilina imedic | Amoxicilina la sante | Amoxicilina
landerlan | Amoxicilina mintlab | Amoxicilina pasteur | Amoxicilina variquin | Amoxicilina vivele
| Amoxiclerc | Amoxidal | Amoxidal duo | Amoxigran | Amoxiland | Amoxilider duo | Amoxilin |
Amoxilin lactante | Amoxilin ninos | Amoximedin | Amoxipen | Amoxsul | Anamox | Antibiopen
| As biotic amoxicilina | Bactilexin | Bioxilina | Blenopack | Carbomox | Compoxilin | Contex
novo | Flogobell biotic | Kefrane | Medamox | Novamox | Novamox duo | Orbenin | Oxibiot |
Pentus | Plamodex | Plamodex duo | Sultrex biotic | Trifamox | Trifamox duo | Trixan; (RO)
Romania: Amoxicilina | Amoxicilina Arena | Amoxicilina atb | Amoxicilina forte | Amoxicilina
sandoz | Amoxicillin sandoz | Duomox | E mox | Ephamox | Moxypen | Ospamox; (RU) Russian
Federation: Amosin | Amoxicillin | Amoxicillin ekobol | Amoxicillin sandoz | Amoxicillin
trihydrate (purimox) | Amoxon | Ecobol | Flemoxin | Gramox d | Hiconcil | Ospamox; (SA) Saudi
Arabia: Amoxil | Amoxipen | Amoxydar | Flemoxin | Glomox | Hiconcil | Hymox | Julphamox |
Moxidad forte | Neomox | Novamoxin | Omacillin | Ospamox | Penamox | Princimox | Remox
| Ultramox; (SE) Sweden: Amimox | Amoxicillin 2care4 | Amoxicillin aurobindo | Amoxicillin ebb
| Amoxicillin mylan | Amoxicillin sandoz | Amoxiferm | Bristamox | Imacillin | Imaxi; (SG)
Singapore: Amox | Amoxapen | Amoxicap | Amoxigran | Amoxil | Amoxycillin | Amyn | Aroxin |
Betamox | Inamox | Lamoxy | Moxilen | Moxipen | Ospamox | Promox | Pulmoxyl | Strimox |
Symoxyl | Synamox | Unimox; (SI) Slovenia: Amoksicillin | Amoxil | Hiconcil | Megamox |
Ospamox; (SK) Slovakia: Amoclen | Amoxihexal | Amoxycillin | Duomox | Ospamox; (SL) Sierra
Leone: Amoxil | Emmox | Miral amoxicillin | Sinoamox; (TH) Thailand: Am moxy f | Amocin |
Amox | Amoxa | Amoxapen | Amoxicillin | Amoxillin | Amoximed | Amoxin | Amoxlin |
Amoxtrin y | Amoxy | Amoxy I.C | Amoxy-T | Amoxycillin | Amoxylin | Ampno | Amyn | Augxil
forte | Augxil G | Auramox | Betamox | Bomox | C-mox | Diamoxycap | Dpf mox | Himox |
Ibiamox | Meixil kids | Milamox n | Mox | Mox run | Moxapen | Moxarin | Moxilin | Moxillin |
Moxipan | Moxipharm | Moxlin | Moxno | Moxxo | Moxycillin | Moxyno | Mymox | Newtamox-
My | Oriamox | Pharmox | Pharmoxcillin | Pinnamox | Premox | Pulmoxyl | Py-Amox |
Pyramox | Ranoxyl | Sanomox g | Sanomox y | Servamox | Starmox | T.O.Cillin | U-Amox |
Unimox | Vamox | Vimoxillin; (TN) Tunisia: Amoxal | Amoxicilline winthrop | Amoxil | Amoxipen
| Amoxydar | Clamoxyl | Hiconcil | Novamox | Penamox | Saifoxyl; (TR) Turkey: Alfoxil |
Amoksilin | Amoksina | Amosin | Atoksilin | Demoksil | Largopen | Moksilin | Remoxil |
Topramoxin | Trimosin; (TW) Taiwan: Amocil | Amocillin | Amolin | Amox | Amoxcin | Amoxi
gobens | Amoxicillin | Amoxicilline | Amoxil | Amoxil paediatric | Amoxycillin | Enmocil |
Hiconcil | Ibiamox | Moxilen | Sawamezin | Servamox | Yisulon; (UA) Ukraine: Amospes |
Amoxicillin | Amoxil | Bactox | Flemoxin | Hiconcil | Ospamox; (UG) Uganda: Agoxin |
Amoxapen | Amoxicap | Amoxicillin | Amoxikid | Amoxil | Amoxiren | Asmox | Brumox |
Classmox | Duramox | Elymox | Farconcil | Hipen | Hiphen | Kam amoxy | Kemoxyl | Medomox
| Miloxy | Moxacil | Moxileb | Moxirone | Penamox | Rivamox | Spamox | Unixil | Xomox; (UY)
Uruguay: Amox-g | Amoxi | Amoxicilina | Amoxicilina phs | Amoxidal | Amoxil | Fabamox |
Farconcil | Fullcilina | Maxibiotic | Moxifar | Moxtam | Ospamox | Princimox | Servamox |
Trifamox duo; (VE) Venezuela, Bolivarian Republic of: Amoxal | Amoxicilina | Amoxiduo |
Amoxilan | Amoxisa | Amylin | Eumoxina | Minoxy | Ospamox | Strimox | Trimoxal | Wellmoxy;
(VN) Viet Nam: Franmoxy | Hagimox | Pms pharmox; (ZA) South Africa: Acucil | Adco-amoxicillin
| Allmox | Amocillin | Amoxicillin | Amoxicillin hexal | Amoxil | Amoxycillin | Amyn | Auro
amoxicillin | Austell amoxicillin | Betamox | C-mox | Ipcamox | Maxcil | Micro-amoxycillin |
Moxan | Moxymax | Moxypen | Norimox | Penmox | Promoxil | Ranmoxy | Rolab-amoxycillin |
Saltermox | Spectramox | Ultramox | Xeracil | Yomax | Zaloxy | Zoxil; (ZM) Zambia: Amocillin |
Amolin | Amoxen | Amoxi denk | Amoxicap | Amoxicillin | Amoxin | Amoxycillin | Amoxykant |
Amyn | Apmox | Camoxy | Dynamox | Elymox | Galmox | Imox | Jetmox | Lamoxy | Miloxy |
Moxileb | Moximon | Moxmar | Moxmed | Moxypen | Neomox | Primox | Spamox | Syamoxil |
Tormoxin | Umoxil | Unixil | Z mox; (ZW) Zimbabwe: Adco Amoxycillin | Amocillin | Amoxen |
Amoxycillin | Balmox 500 | Imox | Medomox | Miloxy | Ranoxyl | Strimox
Use of UpToDate is subject to the Terms of Use.
REFERENCES
1. Afolabi TM, Goodlet KJ, Fairman KA. Association of antibiotic treatment duration with recurrence of
uncomplicated urinary tract infection in pediatric patients. Ann Pharmacother. 2020;54(8):757-766.
doi:10.1177/1060028019900650 [PubMed 31958969]
2. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed
11487763]
3. Ahluwalia J, Abuabara K, Perman MJ, Yan AC. Human herpesvirus 6 involvement in paediatric drug
hypersensitivity syndrome. Br J Dermatol. 2015;172(4):1090-1095. doi:10.1111/bjd.13512 [PubMed
25369238]
4. Ailes EC, Gilboa SM, Gill SK, et al. Association between antibiotic use among pregnant women with urinary
tract infections in the first trimester and birth defects, National Birth Defects Prevention Study 1997 to
2011. Birth Defects Res A Clin Mol Teratol. 2016;106(11):940-949. doi:10.1002/bdra.23570 [PubMed
27891788]
5. Alarcón E, Sansosti A, Navarro B, et al. Amoxicillin-induced aseptic meningitis: 2 case reports and appraisal
of the literature. J Investig Allergol Clin Immunol. 2019;29(3):248-250. doi:10.18176/jiaci.0380 [PubMed
31219042]
6. American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book:
2021 Report of the Committee on Infectious Diseases. 32nd ed. American Academy of Pediatrics; 2021.
7. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics.

Prelabor rupture of membranes: ACOG Practice Bulletin, Number 217. Obstet Gynecol. 2020;135(3):e80-
e97. doi:10.1097/AOG.0000000000003700 [PubMed 32080050]
8. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics.

ACOG Practice Bulletin No. 199: Use of prophylactic antibiotics in labor and delivery. Obstet Gynecol.
2018;132(3):e103-e119. [PubMed 30134425]
9. American College of Obstetricians and Gynecologists (ACOG). Prevention of group B streptococcal early-
onset disease in newborns: ACOG Committee Opinion, Number 797. Obstet Gynecol. 2020;135(2):e51-e72.
doi:10.1097/AOG.0000000000003668 [PubMed 31977795]
10. American Dental Association (ADA); American Academy of Orthopedic Surgeons (AAOS). Antibiotic
prophylaxis for dental patients with total joint replacements. J Am Dent Assoc. 2003;134(7):895-899.
[PubMed 12892448]
11. Amoxicillin [prescribing information]. North Wales, PA: Teva Pharmaceuticals; August 2018.
12. Amoxicillin [prescribing information]. North Wales, PA: Teva Pharmaceuticals; January 2016.
13. Amoxicillin [prescribing information]. Princeton, NJ: Neopharma Inc; September 2019.
14. Amoxil (amoxicillin) [prescribing information]. Bristol, TN: Dr Reddy’s Laboratories; December 2015.
15. Amoxil (amoxicillin) [prescribing information]. Bristol, TN: USAntibiotics LLC; November 2022.
16. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-
52. [PubMed 27060684]
17. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against streptococcus
pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother. 1998;42(9):2375-
2379. doi:10.1128/AAC.42.9.2375 [PubMed 9736566]
18. Andrew MA, Easterling TR, Carr DB, et al. Amoxicillin pharmacokinetics in pregnant women: modeling and
simulations of dosage strategies. Clin Pharmacol Ther. 2007;81(4):547-556. [PubMed 17329990]
19. Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and
Children. 5th ed. Philadelphia, PA: American College of Physicians; 2007:61, 153.
20. Aubier M, Verster R, Regamey C, Geslin P, Vercken JB. Once-daily sparfloxacin versus high-dosage
amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults.
Sparfloxacin European Study Group. Clin Infect Dis. 1998;26(6):1312-1320. doi:10.1086/516366 [PubMed
9636854]
21. Baddour LM, Chen AF. Prosthetic joint infection: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate
Inc. http://www.uptodate.com. Accessed July 14, 2023.
22. Balighian E, Burke M. Urinary tract infections in children. Pediatr Rev. 2018;39(1):3-12.
doi:10.1542/pir.2017-0007 [PubMed 29292282]
23. Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific
statement from the American Heart Association (AHA). Circulation. 2015;132(15):1487-1515. [PubMed
26373317]
24. Barker AF. Bronchiectasis in adults; maintaining lung health. Post TW, ed. UpToDate. Waltham, MA:
UpToDate Inc. http://www.uptodate.com. Accessed July 13, 2023.
25. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002;346(5):334-339.
doi:10.1056/NEJMcp011603 [PubMed 11821511]
26. Belarmino JM and Kogan BA. Management of neonatal hydronephrosis. Early Hum Dev. 2006;82(1):9-14.
[PubMed 16427220]
27. Ben Fredj N, Aouam K, Chaabane A, et al. Hypersensitivity to amoxicillin after drug rash with eosinophilia
and systemic symptoms (DRESS) to carbamazepine and allopurinol: a possible co-sensitization. Br J Clin
Pharmacol. 2010;70(2):273-276. doi:10.1111/j.1365-2125.2010.03685.x [PubMed 20653681]
28. Benyamini L, Merlob P, Stahl B, et al, "The Safety of Amoxicillin/Clavulanic Acid and Cefuroxime During
Lactation," Ther Drug Monit, 2005, 27(4):499-502. [PubMed 16044108]
29. Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet. 2019;393(10167):183-198.
doi:10.1016/S0140-6736(18)32218-9 [PubMed 30558872]
30. Bonnefond S, Catroux M, Melenotte C, et al. Clinical features of actinomycosis: a retrospective, multicenter
study of 28 cases of miscellaneous presentations. Medicine (Baltimore). 2016;95(24):e3923.
doi:10.1097/MD.0000000000003923 [PubMed 27311002]
31. Bontems P, Kalach N, Oderda G, et al. Sequential therapy versus tailored triple therapies for Helicobacter
pylori infection in children. J Pediatr Gastroenterol Nutr. 2011;53(6):646-650.
doi:10.1097/MPG.0b013e318229c769 [PubMed 21701406]
32. Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in
pregnancy. Pharmacotherapy. 2015;35(11):1052-1062. doi:10.1002/phar.1649 [PubMed 26598097]
33. Borges I, Faveri M, Figueiredo LC, et al. Different antibiotic protocols in the treatment of severe chronic
periodontitis: a 1-year randomized trial. J Clin Periodontol. 2017;44(8):822-832. doi:10.1111/jcpe.12721
[PubMed 28303587]
34. Bower WA, Schiffer J, Atmar RL, et al; CDC ACIP Anthrax Vaccine Work Group. Use of anthrax vaccine in the
United States: recommendations of the Advisory Committee on Immunization Practices, 2019. MMWR
Recomm Rep. 2019;68(4):1-14. doi:10.15585/mmwr.rr6804a1 [PubMed 31834290]
35. Bradley JS, Byington CL, Shah SS, et al. “The Management of Community-Acquired Pneumonia in Infants
and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases
Society and the Infectious Diseases Society of America”, Clin Infect Dis, 2011, 53(7):e25-76. [PubMed
21880587]
36. Bradley JS, Garonzik SM, Forrest A, Bhavnani SM. Pharmacokinetics, pharmacodynamics, and Monte Carlo
simulation: selecting the best antimicrobial dose to treat an infection. Pediatr Infect Dis J.
2010;29(11):1043-1046. doi:10.1097/INF.0b013e3181f42a53 [PubMed 20975453]
37. Bradley JS, Nelson JD, Kimberlin DK, et al, eds. Nelson's Pocket Book of Pediatric Antimicrobial Therapy. 28th
ed. American Academy of Pediatrics; 2022.
38. Bradley JS, Peacock G, Krug SE, et al; AAP Committee on Infectious Diseases and Disaster Preparedness
Advisory Council. Pediatric anthrax clinical management. Pediatrics. 2014;133(5):e1411-e1436.
doi:10.1542/peds.2014-0563 [PubMed 24777226]
39. Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-
Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German
Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the
German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact
Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society
for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine
(DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute
for Drugs and Medical Products (BfArM). Allergo J Int. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6
[PubMed 26120552]
40. Brook I. Treatment of actinomycosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.
http://www.uptodate.com. Accessed July 12, 2023.
41. Brown KA, Fisman DN, Moineddin R, Daneman N. The magnitude and duration of Clostridium difficile
infection risk associated with antibiotic therapy: a hospital cohort study. PLoS One. 2014;9(8):e105454.
doi:10.1371/journal.pone.0105454 [PubMed 25157757]
42. Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-
associated Clostridium difficile infection. Antimicrob Agents Chemother. 2013;57(5):2326-2332.
doi:10.1128/AAC.02176-12 [PubMed 23478961]
43. Brown KA, Langford B, Schwartz KL, Diong C, Garber G, Daneman N. Antibiotic prescribing choices and
their comparative C. difficile infection risks: a longitudinal case-cohort study. Clin Infect Dis.
2021;72(5):836-844. doi:10.1093/cid/ciaa124 [PubMed 32069358]
44. Buckingham M, Welply G, Miller JF, Elstein M. Gastro-intestinal absorption and transplacental transfer of
amoxycillin during labour and the influence of metoclopramide. Curr Med Res Opin. 1975;3(6):392-396.
doi:10.1185/03007997509114794 [PubMed 1183221]
45. Buonomo A, Nucera E, Pecora V, et al. Cross-reactivity and tolerability of cephalosporins in patients with
cell-mediated allergy to penicillins. J Investig Allergol Clin Immunol. 2014;24(5):331-337. [PubMed
25345303]
46. Butenko T, Jeverica S, Orel R, Homan M. Antibacterial resistance and the success of tailored triple therapy in
Helicobacter pylori strains isolated from Slovenian children. Helicobacter. 2017;22(5):e12400.
doi:10.1111/hel.12400 [PubMed 28653787]
47. Canafax DM, Yuan Z, Chonmaitree T, Deka K, Russlie HQ, Giebink GS. Amoxicillin middle ear fluid
penetration and pharmacokinetics in children with acute otitis media. Pediatr Infect Dis J. 1998;17(2):149-
156. doi:10.1097/00006454-199802000-00014 [PubMed 9493813]
48. Cardaropoli S, Rolfo A, Todros T. Helicobacter pylori and pregnancy-related disorders. World J
Gastroenterol. 2014;20(3):654-664. doi:10.3748/wjg.v20.i3.654 [PubMed 24574739]
49. Caruso C, Valluzzi RL, Colantuono S, Gaeta F, Romano A. β-lactam allergy and cross-reactivity: a clinician's
guide to selecting an alternative antibiotic. J Asthma Allergy. 2021;14:31-46. doi:10.2147/JAA.S242061
[PubMed 33500632]
50. CDC and Johns Hopkins Working Group on Civilian Biodefense. Commentary on Non-Labeled Dosing of
Oral Amoxicillin in Adults and Pediatrics for Post-Exposure Inhalational Anthrax. December 10, 2001.
http://www.fda.gov/cder/drugprepare/amox-anthrax.htm
51. Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—
United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291.
http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
52. Centers for Disease Control and Prevention (CDC). FAQs for clinicians about C. diff.
https://www.cdc.gov/cdiff/clinicians/faq.html. Updated March 27, 2020. Accessed July 27, 2021 [PubMed
CDC.1]
53. Chew C, Goenka A. QUESTION 2: Does amoxicillin exposure increase the risk of rash in children with acute
Epstein-Barr virus infection? Arch Dis Child. 2016;101(5):500-502. doi:10.1136/archdischild-2015-310364
[PubMed 26893522]
54. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori
infection [published correction appears in Am J Gastroenterol. 2018;113(7):1102]. Am J Gastroenterol.
2017;112(2):212-239. doi:10.1038/ajg.2016.563 [PubMed 28071659]
55. Cho CB. Adverse reactions to drugs. In: Kliegman RM, St. Geme J, eds. Nelson Textbook of Pediatrics. 21st
ed. Elsevier; 2020:chap. 177. [PubMed cho.2020]
56. Choon SE, Der YS, Lai NLJ, Yu SEE, Yap XL, Nalini NM. Clinical characteristics, culprit drugs and outcome of
patients with Acute Generalised Exanthematous Pustulosis seen in Hospital Sultanah Aminah, Johor Bahru.
Med J Malaysia. 2018;73(4):220-225. [PubMed 30121684]
57. Chovel-Sella A, Ben Tov A, Lahav E, et al. Incidence of rash after amoxicillin treatment in children with
infectious mononucleosis. Pediatrics. 2013;131(5):e1424-e1427. doi:10.1542/peds.2012-1575 [PubMed
23589810]
58. Chow AW, Benninger MS, Brook I, et al; Infectious Diseases Society of America. IDSA clinical practice
guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012;54(8):e72-e112.
[PubMed 22438350]
59. Chow AW. Complications, diagnosis, and treatment of odontogenic infections. Post TW, ed. UpToDate.
Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 9, 2022.
60. Christian-Kopp S, Sinha M, Rosenberg DI, Eisenhart AW, McDonald FW. Antibiotic dosing for acute otitis
media in children: a weighty issue. Pediatr Emerg Care. 2010;26(1):19-25.
doi:10.1097/PEC.0b013e3181cbeb00 [PubMed 20042912]
61. Cohen MD, Raeburn JA, Devine J, et al. Pharmacology of some oral penicillins in the newborn infant. Arch
Dis Child. 1975;50(3):230-234. doi:10.1136/adc.50.3.230 [PubMed 1147656]
62. Coignard-Biehler H, Lanternier F, Hot A, et al. Adherence to preventive measures after splenectomy in the
hospital setting and in the community. J Infect Public Health. 2011;4(4):187-194.
doi:10.1016/j.jiph.2011.06.004 [PubMed 22000846]
63. Cole KA, Kenney RM, Perri MB, et al. Outcomes of aminopenicillin therapy for vancomycin-resistant
enterococcal urinary tract infections. Antimicrob Agents Chemother. 2015;59(12):7362-7366. [PubMed
26369973]
64. Connelly S, Subramanian P, Hasan NA, Colwell RR, Kaleko M. Distinct consequences of amoxicillin and
ertapenem exposure in the porcine gut microbiome. Anaerobe. 2018;53:82-93.
doi:10.1016/j.anaerobe.2018.04.012 [PubMed 29689301]
65. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and
men. Clin Infect Dis. 1998;26(1):1-10. doi:10.1086/516284 [PubMed 9455502]
66. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect
Dis J. 1996;15(3):255-259. doi:10.1097/00006454-199603000-00015 [PubMed 8852915]
67. Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy
and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr Adolesc Med.
2009;163(11):978-985. doi:10.1001/archpediatrics.2009.188 [PubMed 19884587]
68. Currie DC, Garbett ND, Chan KL, et al. Double-blind randomized study of prolonged higher-dose oral
amoxycillin in purulent bronchiectasis. Q J Med. 1990;76(280):799-816. [PubMed 2217684]
69. Curtis BR. Non-chemotherapy drug-induced neutropenia: key points to manage the challenges.
Hematology Am Soc Hematol Educ Program. 2017;2017(1):187-193. doi:10.1182/asheducation-2017.1.187
[PubMed 29222255]
70. Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of
congenital malformations: a population-based study. Am J Obstet Gynecol. 2019;221(6):648.e1-648.e15.
doi:10.1016/j.ajog.2019.06.050 [PubMed 31260651]
71. Davies BE, Boon R, Horton R, Reubi FC, Descoeudres CE. Pharmacokinetics of amoxycillin and clavulanic
acid in haemodialysis patients following intravenous administration of augmentin. Br J Clin Pharmacol.
1988;26(4):385-390. doi:10.1111/j.1365-2125.1988.tb03395.x [PubMed 3190988]
72. Davies TA, Kelly LM, Pankuch GA, Credito KL, Jacobs MR, Appelbaum PC. Antipneumococcal activities of
gemifloxacin compared to those of nine other agents. Antimicrob Agents Chemother. 2000;44(2):304-310.
doi:10.1128/aac.44.2.304-310.2000 [PubMed 10639354]
73. De La Cruz AC, Ashraf S, Shrestha N, Saad M. Myocarditis and drug rash with eosinophilia and systemic
symptoms syndrome: a deadly combination. Cureus. 2021;13(2):e13496. doi:10.7759/cureus.13496
[PubMed 33777581]
74. de Rossi P, Cimerman S, Truzzi JC, et al. Joint report of SBI (Brazilian Society of Infectious Diseases),
FEBRASGO (Brazilian Federation of Gynecology and Obstetrics Associations), SBU (Brazilian Society of
Urology) and SBPC/ML (Brazilian Society of Clinical Pathology/Laboratory Medicine): recommendations for
the clinical management of lower urinary tract infections in pregnant and non-pregnant women. Braz J
Infect Dis. 2020;24(2):110-119. doi:10.1016/j.bjid.2020.04.002 [PubMed 32360431]
75. Deshpande A, Pasupuleti V, Thota P, et al. Community-associated Clostridium difficile infection and
antibiotics: a meta-analysis. J Antimicrob Chemother. 2013;68(9):1951-1961. doi:10.1093/jac/dkt129
[PubMed 23620467]
76. Dibek Misirlioglu E, Guvenir H, Ozkaya Parlakay A, et al. Incidence of antibiotic-related rash in children with
Epstein-Barr virus infection and evaluation of the frequency of confirmed antibiotic hypersensitivity. Int
Arch Allergy Immunol. 2018;176(1):33-38. doi:10.1159/000481988 [PubMed 29617685]
77. Di Lernia V, Mansouri Y. Epstein-Barr virus and skin manifestations in childhood. Int J Dermatol.
2013;52(10):1177-1184. doi:10.1111/j.1365-4632.2012.05855.x [PubMed 24073903]
78. Domonoske C. Appendix A: Common neonatal intensive care unit (NICU) medication guidelines. In:
Eichenwald EC, Hansen AR, Martin CR, Stark AR. Cloherty and Stark's Manual of Neonatal Care. 8th edition.
Lippincott Williams & Wilkins; 2017.
79. Donaldson N, Sanders J, Child J, Parker S. Acute hematogenous bacterial osteoarticular infections in
children. Pediatr Rev. 2020;41(3):120-136. doi:10.1542/pir.2018-0201 [PubMed 32123023]
80. Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media: management and surveillance in an era of
pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic
Working Group. Pediatr Infect Dis J. 1999;18(1):1-9. [PubMed 9951971]
81. Dubois J, St-Pierre C. In vitro study of the post-antibiotic effect and the bactericidal activity of cefditoren
and ten other oral antimicrobial agents against upper and lower respiratory tract pathogens. Diagn
Microbiol Infect Dis. 2000;37(3):187-193. doi:10.1016/s0732-8893(00)00141-3 [PubMed 10904192]
82. Exius R, Gabrielli S, Abrams EM, et al. Establishing Amoxicillin Allergy in Children Through Direct Graded
Oral Challenge (GOC): Evaluating Risk Factors for Positive Challenges, Safety, and Risk of Cross-Reactivity to
Cephalosporines. J Allergy Clin Immunol Pract. Published online July 19, 2021.
doi:10.1016/j.jaip.2021.06.057 [PubMed 34293504]
83. Fallon RM, Kuti JL, Doern GV, Girotto JE, Nicolau DP. Pharmacodynamic target attainment of oral beta-
lactams for the empiric treatment of acute otitis media in children. Paediatr Drugs. 2008;10(5):329-335.
doi:10.2165/00148581-200810050-00006 [PubMed 18754699]
84. Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori
infection in adults. Gastroenterology. 2016;151(1):51-69.e14. [PubMed 27102658]
85. File TM. Treatment of community-acquired pneumonia in adults in the outpatient setting. Post TW, ed.
UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 23, 2023b.
86. File TM. Treatment of community-acquired pneumonia in adults who require hospitalization. Post TW, ed.
UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 14, 2023a.
87. Finegold SM, Gentry LO, Mogabgab W, Campbell SC, Skatrud J. Controlled comparative trial of
bacampicillin and amoxicillin in therapy of bacterial infections of the lower respiratory tract. Rev Infect Dis.
1981;3(1):150-153. [PubMed 7012996]
88. Fonseca W, Hoppu K, Rey LC, Amaral J, Qazi S. Comparing pharmacokinetics of amoxicillin given twice or
three times per day to children older than 3 months with pneumonia. Antimicrob Agents Chemother.
2003;47(3):997-1001. doi:10.1128/aac.47.3.997-1001.2003 [PubMed 12604533]
89. Fox MT, Amoah J, Hsu AJ, Herzke CA, Gerber JS, Tamma PD. Comparative effectiveness of antibiotic
treatment duration in children with pyelonephritis. JAMA Netw Open. 2020;3(5):e203951.
doi:10.1001/jamanetworkopen.2020.3951 [PubMed 32364593]
90. Francke EL, Appel GB, Neu HC. Kinetics of intravenous amoxicillin in patients on long-term dialysis. Clin
Pharmacol Ther. 1979;26(1):31-35. doi:10.1002/cpt197926131 [PubMed 445959]
91. Garbutt J, St Geme JW 3rd, May A, Storch GA, Shackelford PG. Developing community-specific
recommendations for first-line treatment of acute otitis media: is high-dose amoxicillin necessary?
Pediatrics. 2004;114(2):342-347. doi:10.1542/peds.114.2.342 [PubMed 15286214]
92. Garbutt JM, Banister C, Spitznagel E, Piccirillo JF. Amoxicillin for acute rhinosinusitis: a randomized
controlled trial. JAMA. 2012;307(7):685-692. [PubMed 22337680]
93. García-Porrúa C, González-Gay MA, López-Lázaro L. Drug associated cutaneous vasculitis in adults in
northwestern Spain. J Rheumatol. 1999;26(9):1942-1944. [PubMed 10493674]
94. Garrison GD, Sorum PC, Hioe W, Miller MM. High-dose versus standard-dose amoxicillin for acute otitis
media. Ann Pharmacother. 2004;38(1):15-19. doi:10.1345/aph.1D052 [PubMed 14742786]
95. Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of
acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic
Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the
Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the
Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of
Pediatrics. Circulation. 2009;119(11):1541-1551. doi:10.1161/CIRCULATIONAHA.109.191959 [PubMed
19246689]
96. Gillies M, Ranakusuma A, Hoffmann T, et al. Common harms from amoxicillin: a systematic review and
meta-analysis of randomized placebo-controlled trials for any indication. CMAJ. 2015;187(1):E21-E31.
doi:10.1503/cmaj.140848 [PubMed 25404399]
97. Girelli F, Bernardi S, Gardelli L, et al. A new case of DRESS syndrome induced by sulfasalazine and triggered
by amoxicillin. Case Rep Rheumatol. 2013;2013:409152. doi:10.1155/2013/409152 [PubMed 23936716]
98. Goldstein LH, Berlin M, Tsur L, Bortnik O, Binyamini L, Berkovitch M. The safety of macrolides during
lactation. Breastfeed Med. 2009;4(4):197-200. [PubMed 19366316]
99. Golightly LK, Teitelbaum I, Kiser TH, et al, eds. Renal Pharmacotherapy: Dosage Adjustment of Medications
Eliminated by the Kidneys. New York, NY: Springer Science; 2013.
100. Green SM, Rothrock SG. Single-dose intramuscular ceftriaxone for acute otitis media in children. Pediatrics.
1993;91(1):23-30. [PubMed 8416502]
101. Greenbaum LA and Mesrobian HG. Vesicoureteral reflux. Pediatr Clin North Am. 2006;53(3):413-427.
[PubMed 16716788]
102. Gupta K. Acute simple cystitis in females. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.
http://www.uptodate.com. Accessed July 14, 2023b.
103. Gupta K. Urinary tract infections and asymptomatic bacteriuria in pregnancy. Post TW, ed. UpToDate.
Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 14, 2023a.
104. Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for
Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute
uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of
America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis.
2011;52(5):e103-e120. doi:10.1093/cid/ciq257 [PubMed 21292654]
105. Gustafsson I, Löwdin E, Odenholt I, Cars O. Pharmacokinetic and pharmacodynamic parameters for
antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model. Antimicrob Agents
Chemother. 2001;45(9):2436-2440. doi:10.1128/aac.45.9.2436-2440.2001 [PubMed 11502511]
106. Halperin JJ, Shapiro ED, Logigian E, et al. Practice parameter: treatment of nervous system Lyme disease (an
evidence-based review): report of the Quality Standards Subcommittee of the American Academy of
Neurology. Neurology. 2007;69(1):91-102. [PubMed 17522387]
107. Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and for
the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract
infection in adults: advice for high-value care from the American College of Physicians and the Centers for
Disease Control and Prevention. Ann Intern Med. 2016;164(6):425-434. [PubMed 26785402]
108. Hendricks KA, Wright ME, Shadomy SV, et al; Workgroup on Anthrax Clinical Guidelines. Centers for Disease
Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg
Infect Dis. 2014;20(2). doi:10.3201/eid2002.130687 [PubMed 24447897]
109. Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile
infection after exposure to antibiotics. J Antimicrob Chemother. 2012;67(3):742-748.
doi:10.1093/jac/dkr508 [PubMed 22146873]
110. Hoberman A, Paradise JL, Rockette HE, et al. Shortened antimicrobial treatment for acute otitis media in
young children. N Engl J Med. 2016;375(25):2446-2456. doi:10.1056/NEJMoa1606043 [PubMed 28002709]
111. Homme JH. Acute otitis media and group A streptococcal pharyngitis: a review for the general pediatric
practitioner. Pediatr Ann. 2019;48(9):e343-e348. doi:10.3928/19382359-20190813-01 [PubMed 31505007]
112. Hsu K. Treatment of Chlamydia trachomatis infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.
http://www.uptodate.com. Accessed July 14, 2023.
113. Hu L. Treatment of Lyme disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.
http://www.uptodate.com. Accessed September 29, 2021.
114. Hum SW, Shaikh KJ, Musa SS, Shaikh N. Adverse events of antibiotics used to treat acute otitis media in
children: a systematic meta-analysis. J Pediatr. 2019;215:139-143.e7. [PubMed 31561959]
115. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics
(AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
116. Isla A, Trocóniz IF, Canut A, et al. Pharmacokinetic/pharmacodynamic evaluation of amoxicillin,

amoxicillin/clavulanate and ceftriaxone in the treatment of paediatric acute otitis media in Spain. Enferm
Infecc Microbiol Clin. 2011;29(3):167-173. doi:10.1016/j.eimc.2010.05.008 [PubMed 21334779]
117. Ito S, Blajchman A, Stephenson M, et al. Prospective Follow-Up of Adverse Reactions in Breast-Fed Infants
Exposed to Maternal Medication. Am J Obstet Gynecol. 1993;168(5):1393-1399. [PubMed 8498418]
118. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126. [PubMed 10891521]
119. Iwańczak BM, Borys-Iwanicka A, Biernat M, Gościniak G. Assessment of sequential and standard triple
therapy in treatment of Helicobacter pylori infection in children dependent on bacteria sensitivity to
antibiotics. Adv Clin Exp Med. 2016;25(4):701-708. doi:10.17219/acem/38554 [PubMed 27629844]
120. Jacobson GF, Autry AM, Kirby RS, Liverman EM, Motley RU. A randomized controlled trial comparing
amoxicillin and azithromycin for the treatment of Chlamydia trachomatis in pregnancy. Am J Obstet
Gynecol. 2001;184(7):1352-1354. doi:10.1067/mob.2001.115050 [PubMed 11408852]
121. Jevsevar DS, Abt E. The New AAOS-ADA Clinical Practice Guideline on Prevention of Orthopaedic Implant
Infection in Patients Undergoing Dental Procedures. J Am Acad Orthop Surg. 2013;21(3):195-197. [PubMed
23457071]
122. Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN guidelines for the management of
Helicobacter pylori in children and adolescents (update 2016). J Pediatr Gastroenterol Nutr. 2017;64(6):991-
1003. doi:10.1097/MPG.0000000000001594 [PubMed 28541262]
123. Kafetzis DA, Siafas CA, Georgakopoulos PA, Papadatos CJ. Passage of cephalosporins and amoxicillin into
the breast milk. Acta Paediatr Scand. 1981;70(3):285-288. [PubMed 7246123]
124. Kanhutu K, Jones P, Cheng AC, Grannell L, Best E, Spelman D. Spleen Australia guidelines for the prevention
of sepsis in patients with asplenia and hyposplenism in Australia and New Zealand. Intern Med J.
2017;47(8):848-855. doi:10.1111/imj.13348 [PubMed 27925427]
125. Katoh Y, Natsume O, Matsunaga M, Takayanagi F, Uchida H, Yasuoka R. Diagnosis of non-immediate

hypersensitivity to amoxicillin in children by skin test and drug provocation tests: a retrospective case-series
study. Allergol Int. Published online August 9, 2021. doi:10.1016/j.alit.2021.07.009 [PubMed 34384710]
126. Keij FM, Kornelisse RF, Hartwig NG, Reiss IKM, Allegaert K, Tramper-Stranders GA. Oral antibiotics for
neonatal infections: a systematic review and meta-analysis. J Antimicrob Chemother. 2019;74(11):3150-
3161. doi:10.1093/jac/dkz252 [PubMed 31236572]
127. Keller F, Schröppel B, Ludwig U. Pharmacokinetic and pharmacodynamic considerations of antimicrobial

drug therapy in cancer patients with kidney dysfunction. World J Nephrol. 2015;4(3):330-344.
doi:10.5527/wjn.v4.i3.330 [PubMed 26167456]
128. Kim JS, Jang YR, Lee JW, et al. A case of amoxicillin-induced hepatocellular liver injury with bile-duct
damage. Korean J Hepatol. 2011;17(3):229-232. doi:10.3350/kjhep.2011.17.3.229 [PubMed 22102391]
129. Koletzko S, Jones NL, Goodman KJ, et al. Evidence-based guidelines from ESPGHAN and NASPGHAN for
Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr. 2011;53(2):230-243. [PubMed
21558964]
130. Koosakulchai V, Sangsupawanich P, Wantanaset D, Jessadapakorn W, Jongvilaikasem P, Yuenyongviwat A.

Safety of direct oral provocation testing using the amoxicillin-2-step-challenge in children with history of
non-immediate reactions to amoxicillin. World Allergy Organ J. 2021;14(7):100560.
doi:10.1016/j.waojou.2021.100560 [PubMed 34306301]
131. Kozyrskyj A, Klassen TP, Moffatt M, Harvey K. Short-course antibiotics for acute otitis media. Cochrane
Database Syst Rev. 2010;2010(9):CD001095. doi:10.1002/14651858.CD001095.pub2 [PubMed 20824827]
132. Kuehn J, Ismael Z, Long PF, Barker CI, Sharland M. Reported rates of diarrhea following oral penicillin
therapy in pediatric clinical trials. J Pediatr Pharmacol Ther. 2015;20(2):90-104. doi:10.5863/1551-6776-
20.2.90 [PubMed 25964726]
133. Kuitunen I, Jääskeläinen J, Korppi M, Renko M. Antibiotic treatment duration for community acquired
pneumonia in outpatient children in high-income countries - a systematic review and meta-analysis. Clin
Infect Dis. 2022;ciac374. doi:10.1093/cid/ciac374 [PubMed 35579504]
134. Kutluk G, Tutar E, Bayrak A, et al. Sequential therapy versus standard triple therapy for Helicobacter pylori
eradication in children: any advantage in clarithromycin-resistant strains?. Eur J Gastroenterol Hepatol.
2014;26(11):1202-1208. doi:10.1097/MEG.0000000000000190 [PubMed 25171023]
135. Lambert JS. An overview of tickborne infections in pregnancy and outcomes in the newborn: the need for
prospective studies. Front Med (Lausanne). 2020;7:72. doi:10.3389/fmed.2020.00072 [PubMed 32211414]
136. Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: a current review of
resistance, immunomodulation and teratogenicity. Expert Opin Drug Saf. 2014;13(12):1569-1581.
doi:10.1517/14740338.2014.939580 [PubMed 25189188]
137. Lamont TJ. Treatment regimens for helicobacter pylori in adults. Post TW, ed. UpToDate. Waltham, MA:
UpToDate Inc. http://www.uptodate.com. Accessed July 14, 2023.
138. Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the Infectious Diseases Society
of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR):
2020 guidelines for the prevention, diagnosis, and treatment of lyme disease. Arthritis Care Res (Hoboken).
2021;73(1):1-9. doi:10.1002/acr.24495 [PubMed 33251700]
139. Lashkar MO, Nahata MC. Antimicrobial pharmacotherapy management of urinary tract infections in
pediatric patients. J Pharm Technol. 2018;34(2):62-81. doi:10.1177/8755122518755402 [PubMed 34860955]
140. Lee GM. Preventing infections in children and adults with asplenia. Hematology Am Soc Hematol Educ
Program. 2020;2020(1):328-335. doi:10.1182/hematology.2020000117 [PubMed 33275684]
141. Lee SY. Postantibiotic effects and postantibiotic sub-MIC effects of amoxicillin on streptococcus gordonii
and streptococcus sanguis. J Chemother. 2000;12(5):379-384. doi:10.1179/joc.2000.12.5.379 [PubMed
11128556]
142. Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media.
Pediatrics. 2013;131(3):e964-e999. doi:10.1542/peds.2012-3488 [PubMed 23439909]
143. Limb CJ, Lustig LR, Durand ML. Acute otitis media in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate
Inc. http://www.uptodate.com. Accessed July 14, 2023.
144. Lin KJ, Mitchell AA, Yau WP, Louik C, Hernandez-Diaz S. Maternal exposure to amoxicillin and the risk of oral
clefts. Epidemiology. 2012;23(5):699-705. [PubMed 22766750]
145. Lindbaek M, Hjortdahl P, Johnsen UL. Randomised, double blind, placebo controlled trial of penicillin V and
amoxycillin in treatment of acute sinus infections in adults. BMJ. 1996;313(7053):325-329. [PubMed
8760738]
146. Litao G, Jingjing S, Yu L, Lei Z, Xiaona H, Zhijing Z. Risk factors for antibiotic-associated diarrhea in critically
ill patients. Med Sci Monit. 2018;24:5000-5007. doi:10.12659/MSM.911308 [PubMed 30020891]
147. Lockhart PB, Tampi MP, Abt E, et al. Evidence-based clinical practice guideline on antibiotic use for the
urgent management of pulpal- and periapical-related dental pain and intraoral swelling: A report from the
American Dental Association. J Am Dent Assoc. 2019;150(11):906-921.e12. doi:10.1016/j.adaj.2019.08.020

[PubMed 31668170]
148. Lönnerholm G, Bengtsson S, Ewald U. Oral pivampicillin and amoxycillin in newborn infants. Scand J Infect
Dis. 1982;14(2):127-130. doi:10.3109/inf.1982.14.issue-2.10 [PubMed 7100823]
149. Lusk RH, Fekety FR Jr, Silva J Jr, et al. Gastrointestinal side effects of clindamycin and ampicillin therapy. J
Infect Dis. 1977;135 suppl:S111-S119. doi:10.1093/infdis/135.supplement.s111 [PubMed 850084]
150. Ma H, Zhang L, Zhang Y, Liu Y, He Y, Guo L. Combined administration of antibiotics increases the incidence
of antibiotic-associated diarrhea in critically ill patients. Infect Drug Resist. 2019;12:1047-1054.
doi:10.2147/IDR.S194715 [PubMed 31118710]
151. Mandel EM, Kardatzke D, Bluestone CD, Rockette HE. A comparative evaluation of cefaclor and amoxicillin
in the treatment of acute otitis media. Pediatr Infect Dis J. 1993;12(9):726-732. doi:10.1097/00006454-
199309000-00005 [PubMed 8414799]
152. Mantegazza C, Molinari P, D'Auria E, Sonnino M, Morelli L, Zuccotti GV. Probiotics and antibiotic-associated
diarrhea in children: a review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic
treatment. Pharmacol Res. 2018;128:63-72. doi:10.1016/j.phrs.2017.08.001 [PubMed 28827186]
153. Marchisio P, Galli L, Bortone B, et al. Updated guidelines for the management of acute otitis media in
children by the Italian Society of Pediatrics: treatment. Pediatr Infect Dis J. 2019;38(12S suppl):S10-S21.
doi:10.1097/INF.0000000000002452 [PubMed 31876601]
154. Martin MV. The use of oral amoxycillin for the treatment of actinomycosis. A clinical and in vitro study. Br
Dent J. 1984;156(7):252-254. [PubMed 6584159]
155. Mattoo TK. Medical management of vesicoureteral reflux - quiz within the article. Don't overlook placebos.
Pediatr Nephrol. 2007;22(8):1113-1120. [PubMed 17483966]
156. McCormick DP, Chonmaitree T, Pittman C, et al. Nonsevere acute otitis media: a clinical trial comparing
outcomes of watchful waiting versus immediate antibiotic treatment. Pediatrics. 2005;115(6):1455-1465.
doi:10.1542/peds.2004-1665 [PubMed 15930204]
157. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in
adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for
Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085
[PubMed 29462280]
158. McFarland LV, Ozen M, Dinleyici EC, Goh S. Comparison of pediatric and adult antibiotic-associated
diarrhea and Clostridium difficile infections. World J Gastroenterol. 2016;22(11):3078-3104.
doi:10.3748/wjg.v22.i11.3078 [PubMed 27003987]
159. Meaney-Delman D, Zotti ME, Creanga AA, et al; Workgroup on Anthrax in Pregnant and Postpartum
Women. Special considerations for treatment of anthrax in pregnant and postpartum women. Emerg Infect
Dis. 2014;20(2). [PubMed 24457117]
160. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired
pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases
Society of America. Am J Resp Crit Care Med. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST
[PubMed 31573350]
161. Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force statement on the management of
reproduction and pregnancy in women with airways diseases. Eur Respir J. 2020;55(2):1901208.
doi:10.1183/13993003.01208-2019 [PubMed 31699837]
162. Mir F, Pearce RE, Baig-Ansari N, et al. Serum amoxicillin levels in young infants (0-59 days) with sepsis
treated with oral amoxicillin. Arch Dis Child. 2020;105(12):1208-1214. doi:10.1136/archdischild-2019-
317342 [PubMed 32404437]
163. Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline:
management of dyspepsia. Am J Gastroenterol. 2017;112(7):988-1013. doi:10.1038/ajg.2017.154 [PubMed
28631728]
164. Moghimi M, Salentijn E, Debets-Ossenkop Y, Karagozoglu KH, Forouzanfar T. Treatment of cervicofacial

actinomycosis: a report of 19 cases and review of literature. Med Oral Patol Oral Cir Bucal. 2013;18(4):e627-
e632. [PubMed 23722146]
165. Mohsenzadeh A, Movahedi M, Saatchi M, et al. Serum sickness-like reactions in Iranian children: a registry-
based study in a referral center. Allergol Immunopathol (Madr). 2020;48(5):424-429.
doi:10.1016/j.aller.2019.07.012 [PubMed 32653225]
166. Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and the risk of major congenital
malformations: a population based cohort study. Br J Clin Pharmacol. 2017a;83(11):2557-2571.
doi:10.1111/bcp.13364 [PubMed 28722171]
167. Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion.
CMAJ. 2017b;189(17):E625-E633. doi:10.1503/cmaj.161020 [PubMed 28461374]
168. Muller AE, Oostvogel PM, DeJongh J, et al. Pharmacokinetics of amoxicillin in maternal, umbilical cord, and
neonatal sera. Antimicrob Agents Chemother. 2009;53(4):1574-1580. [PubMed 19164154]
169. Murray BE. Treatment of enterococcal infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.
http://www.uptodate.com. Accessed February 8, 2021.
170. Musher DM, Bartlett JG, Doern GV. A fresh look at the definition of susceptibility of Streptococcus
pneumoniae to beta-lactam antibiotics. Arch Intern Med. 2001;161(21):2538-2544.
doi:10.1001/archinte.161.21.2538 [PubMed 11718584]
171. Nasiri MJ, Goudarzi M, Hajikhani B, Ghazi M, Goudarzi H, Pouriran R. Clostridioides (Clostridium) difficile
infection in hospitalized patients with antibiotic-associated diarrhea: a systematic review and meta-
analysis. Anaerobe. 2018;50:32-37. doi:10.1016/j.anaerobe.2018.01.011 [PubMed 29408016]
172. National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. Published
September 3, 2014. Accessed October 5, 2021. https://www.nice.org.uk/guidance/cg183
173. National Institute for Health and Care Excellence (NICE). Otitis media (acute): antimicrobial prescribing.
London, UK: National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng91.
Published March 2018. Accessed November 3, 2022.
174. Nguyen CT, Davis KA, Nisly SA, Li J. Treatment of Helicobacter pylori in special patient populations.
Pharmacotherapy. 2019;39(10):1012-1022. doi:10.1002/phar.2318 [PubMed 31400244]
175. Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic
bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis. 2019;68(10):1611-
1615. doi:10.1093/cid/ciz021 [PubMed 31506700]
176. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for
the management of patients with valvular heart disease: a report of the American College of
Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol.
2017;70(2):252-289. doi:10.1016/j.jacc.2017.03.011 [PubMed 28315732]
177. Novamoxin (amoxicillin) [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; May 2023.
178. Osmon DR, Berbari EF, Berendt AR, et al; Infectious Diseases Society of America. Diagnosis and
management of prosthetic joint infection: clinical practice guideline by the Infectious Diseases Society of
America. Clin Infect Dis. 2013;56(1):e1-e25. [PubMed 23223583]
179. Parry MF, “The Penicillins,” Med Clin North Am, 1987, 71(6):1093-112. [PubMed 3320613]
180. Patel ZM, Hwang PH. Uncomplicated acute sinusitis and rhinosinusitis in adults: treatment. Post TW, ed.
UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 14, 2023.
181. Paulo CO, Jordão S, Correia-Pinto J, Ferreira F, Neves I. Actinomycosis, a lurking threat: a report of 11 cases
and literature review. Rev Soc Bras Med Trop. 2018;51(1):7-13. doi:10.1590/0037-8682-0215-2017 [PubMed
29513846]
182. Pavlos R, White KD, Wanjalla C, Mallal SA, Phillips EJ. Severe delayed drug reactions: role of genetics and
viral infections. Immunol Allergy Clin North Am. 2017;37(4):785-815. doi:10.1016/j.iac.2017.07.007
[PubMed 28965641]
183. Peled N, Pitlik S, Samra Z, Kazakov A, Bloch Y, Bishara J. Predicting Clostridium difficile toxin in hospitalized
patients with antibiotic-associated diarrhea. Infect Control Hosp Epidemiol. 2007;28(4):377-381.
doi:10.1086/513723 [PubMed 17385141]
184. Pernica JM, Harman S, Kam AJ, et al. Short-course antimicrobial therapy for pediatric community-acquired
pneumonia: the SAFER Randomized Clinical Trial. JAMA Pediatr. 2021;175(5):475-482.
doi:10.1001/jamapediatrics.2020.6735 [PubMed 33683325]
185. Petitpretz P, Arvis P, Marel M, Moita J, Urueta J; CAP5 Moxifloxacin Study Group. Oral moxifloxacin vs high-
dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal
pneumonia in adults. Chest. 2001;119(1):185-195. doi:10.1378/chest.119.1.185 [PubMed 11157603]
186. Piotin A, Godet J, Trubiano JA, et al. Predictive factors of amoxicillin immediate hypersensitivity and
validation of PEN-FAST clinical decision rule. Ann Allergy Asthma Immunol. Published online July 13, 2021.
doi:10.1016/j.anai.2021.07.005 [PubMed 34271183]
187. Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the
management of adult bronchiectasis. Eur Respir J. 2017;50(3):pii:1700629. doi:10.1183/13993003.00629-
2017 [PubMed 28889110]
188. Price VE, Blanchette VS, Ford-Jones EL. The prevention and management of infections in children with
asplenia or hyposplenia. Infect Dis Clin North Am. 2007;21(3):697-710. [PubMed 17826619]
189. Prigogine T, Glupczynski Y, Carpiaux JP, Blogie M, Yourassowsky E, Schmerber JS. Enoxacin in acute
exacerbations of chronic bronchitis: a comparison with amoxycillin. J Antimicrob Chemother. 1988;21(suppl
B):131-136. [PubMed 3129390]
190. Puhó EH, Szunyogh M, Métneki J, Czeizel AE. Drug treatment during pregnancy and isolated orofacial clefts
in Hungary. Cleft Palate Craniofac J. 2007;44(2):194-202. [PubMed 17328645]
191. Pukander JS, Jero JP, Kaprio EA, Sorri MJ. Clarithromycin vs. amoxicillin suspensions in the treatment of
pediatric patients with acute otitis media. Pediatr Infect Dis J. 1993;12(12 suppl 3):S118-S121.
doi:10.1097/00006454-199312003-00005 [PubMed 8295812]
192. Pullen J, Stolk LM, Nieman FH, Degraeuwe PL, van Tiel FH, Zimmermann LJ. Population pharmacokinetics
and dosing of amoxicillin in (pre)term neonates. Ther Drug Monit. 2006;28(2):226-231.
doi:10.1097/01.ftd.0000198648.39751.11 [PubMed 16628135]
193. Reboli AC. Erysipelothrix infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.
http://www.uptodate.com. Accessed September 10, 2020.
194. Refer to manufacturer's labeling.
195. Rodríguez-Martín S, Martín-Merino E, Lerma V, et al. Active surveillance of severe cutaneous adverse
reactions: a case-population approach using a registry and a health care database. Pharmacoepidemiol
Drug Saf. 2018;27(9):1042-1050. doi:10.1002/pds.4622 [PubMed 30051945]
196. Romano A, Gaeta F, Valluzzi RL, Maggioletti M, Caruso C, Quaratino D. Cross-reactivity and tolerability of
aztreonam and cephalosporins in subjects with a T cell-mediated hypersensitivity to penicillins. J Allergy
Clin Immunol. 2016;138(1):179-186. doi:10.1016/j.jaci.2016.01.025 [PubMed 27016799]
197. Romano A, Valluzzi RL, Caruso C, Maggioletti M, Quaratino D, Gaeta F. Cross-reactivity and tolerability of
cephalosporins in patients with IgE-mediated hypersensitivity to penicillins. J Allergy Clin Immunol Pract.
2018;6(5):1662-1672. doi:10.1016/j.jaip.2018.01.020 [PubMed 29408440]
198. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis.
Otolaryngol Head Neck Surg. 2015;152(2)(suppl):S1-S39. doi:10.1177/0194599815572097 [PubMed
25832968]
199. Rossi F, Ruggiero S, Gallo M, Simeone G, Matarese SM, Nobili B. Amoxicillin-induced hemolytic anemia in a
child with glucose 6-phosphate isomerase deficiency. Ann Pharmacother. 2010;44(7-8):1327-1329.
doi:10.1345/aph.1P030 [PubMed 20516363]
200. Saavedra-Lozano J, Falup-Pecurariu O, Faust SN, et al. Bone and joint infections. Pediatr Infect Dis J.
2017;36(8):788-799. doi:10.1097/INF.0000000000001635 [PubMed 28708801]
201. Salvadori MI, Price VE; Canadian Paediatric Society, Infectious Diseases and Immunization Committee.
Preventing and treating infections in children with asplenia or hyposplenia. Paediatr Child Health.
2014;19(5):271-278. [PubMed 24855431]
202. Same RG, Amoah J, Hsu AJ, et al. The association of antibiotic duration with successful treatment of
community-acquired pneumonia in children. J Pediatric Infect Dis Soc. 2021;10(3):267-273.
doi:10.1093/jpids/piaa055 [PubMed 32525203]
203. Schliamser SE, Cars O, Norrby SR. Neurotoxicity of beta-lactam antibiotics: predisposing factors and
pathogenesis. J Antimicrob Chemother. 1991;27(4):405-425. [PubMed 1856121]
204. Scholz H, Noack R. Multicenter, randomized, double-blind comparison of erythromycin estolate versus
amoxicillin for the treatment of acute otitis media in children. AOM Study Group. Eur J Clin Microbiol Infect
Dis. 1998;17(7):470-478. doi:10.1007/BF01691129 [PubMed 9764549]
205. Schrüfer P, Brockow K, Stoevesandt J, Trautmann A. Predominant patterns of β-lactam hypersensitivity in a

single German Allergy Center: exanthem induced by aminopenicillins, anaphylaxis by cephalosporins.
Allergy Asthma Clin Immunol. 2020;16(1):102. doi:10.1186/s13223-020-00488-0 [PubMed 33292467]
206. Schwarzer A, Urruzuno P, Iwańczak B, et al. New effective treatment regimen for children infected with a
double-resistant Helicobacter pylori strain. J Pediatr Gastroenterol Nutr. 2011;52(4):424-428.
doi:10.1097/MPG.0b013e3181fc8c58 [PubMed 21407111]
207. Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter
pylori infection: expert review. Gastroenterology. 2021;160(5):1831-1841. doi:10.1053/j.gastro.2020.11.059
[PubMed 33524402]
208. Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines
for the diagnosis and management of infectious diarrhea. Clin Infect Dis. 2017;65(12):e45-e80.
doi:10.1093/cid/cix669 [PubMed 29053792]
209. Shulman ST, Bisno AL, Clegg HW, et al; Infectious Diseases Society of America. Clinical practice guideline for
the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious
Diseases Society of America [published correction appears in Clin Infect Dis. 2014;58(10):1496]. Clin Infect
Dis. 2012;55(10):e86-e102. [PubMed 22965026]
210. Silva-Senem MX, Heller D, Varela VM, Torres MC, Feres-Filho EJ, Colombo AP. Clinical and microbiological
effects of systemic antimicrobials combined to an anti-infective mechanical debridement for the
management of aggressive periodontitis: a 12-month randomized controlled trial. J Clin Periodontol.
2013;40(3):242-251. doi:10.1111/jcpe.12052 [PubMed 23297772]
211. Siqueira MB, Saleh A, Klika AK, et al. Chronic suppression of periprosthetic joint infections with oral
antibiotics increases infection-free survivorship. J Bone Joint Surg Am. 2015;97(15):1220-1232.
doi:10.2106/JBJS.N.00999 [PubMed 26246256]
212. Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic
review and meta-analysis. J Antimicrob Chemother. 2014;69(4):881-891. doi:10.1093/jac/dkt477 [PubMed
24324224]
213. Smith GN, Moore KM, Hatchette TF, Nicholson J, Bowie W, Langley JM. Committee Opinion No. 399:
Management of tick bites and Lyme disease during pregnancy. J Obstet Gynaecol Can. 2020;42(5):644-653.
doi:10.1016/j.jogc.2020.01.001 [PubMed 32414479]
214. Sollecito TP, Abt E, Lockhart PB, et al. The use of prophylactic antibiotics prior to dental procedures in
patients with prosthetic joints: Evidence-based clinical practice guideline for dental practitioners--a report
of the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2015;146(1):11-16.
[PubMed 25569493]
215. Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: Treatment. Post TW, ed. UpToDate.
Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 17, 2022.
216. Spoială EL, Stanciu GD, Bild V, Ababei DC, Gavrilovici C. From evidence to clinical guidelines in antibiotic
treatment in acute otitis media in children. Antibiotics (Basel). 2021;10(1):52.
doi:10.3390/antibiotics10010052 [PubMed 33419114]
217. Stein R, Dogan HS, Hoebeke P, et al. Urinary tract infections in children: EAU/ESPU guidelines. Eur Urol.
2015;67(3):546-558. doi:10.1016/j.eururo.2014.11.007 [PubMed 25477258]
218. Stevens DL, Bisno AL, Chambers HF, et al; Infectious Diseases Society of America. Practice guidelines for the
diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases
Society of America. Clin Infect Dis. 2014;59(2):e10-e52. doi:10.1093/cid/ciu444 [PubMed 24973422]
219. Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and
the risk of Clostridium difficile infection. Clin Infect Dis. 2011;53(1):42-48. doi:10.1093/cid/cir301 [PubMed
21653301]
220. Swaminathan S, Alangaden GJ. Treatment of resistant enterococcal urinary tract infections. Curr Infect Dis
Rep. 2010;12(6):455-464. [PubMed 21308555]
221. Szajewska H, Albrecht P, Topczewska-Cabanek A. Randomized, double-blind, placebo-controlled trial: effect

of lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during
treatment in children. J Pediatr Gastroenterol Nutr. 2009;48(4):431-436.
doi:10.1097/mpg.0b013e318182e716 [PubMed 19330931]
222. Szeto CC, Li PK, Johnson DW, et al. ISPD Catheter-related infection recommendations: 2017 update. Perit
Dial Int. 2017;37(2):141-154. doi:10.3747/pdi.2016.00120 [PubMed 28360365]
223. Takimoto R, Honda T, Kataoka TR, Ueshima C, Otsuka A, Kabashima K. DIHS/DRESS-like eruption possibly
induced by amoxicillin during treatment with nivolumab. Eur J Dermatol. 2019;29(2):228-229.
doi:10.1684/ejd.2019.3522 [PubMed 30973334]
224. Thienvibul C, Vachiramon V, Chanprapaph K. Five-year retrospective review of acute generalized

exanthematous pustulosis. Dermatol Res Pract. 2015;2015:260928. doi:10.1155/2015/260928 [PubMed
26783390]
225. Tikmani SS, Muhammad AA, Shafiq Y, et al. Ambulatory treatment of fast breathing in young infants aged
<60 days: a double-blind, randomized, placebo-controlled equivalence trial in low-income settlements of
Karachi. Clin Infect Dis. 2017;64(2):184-189. doi:10.1093/cid/ciw690 [PubMed 27941119]
226. Tomblyn M, Chiller T, Einsele H, et al; Center for International Blood and Marrow Research; National
Marrow Donor program; European Blood and Marrow Transplant Group; American Society of Blood and
Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of
America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and
Infectious Disease Canada; Centers for Disease Control and Prevention. Guidelines for preventing infectious
complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood
Marrow Transplant. 2009;15(10):1143-1238. doi:10.1016/j.bbmt.2009.06.019 [PubMed 19747629]
227. Tshefu A, Lokangaka A, African Neonatal Sepsis Trial (AFRINEST) group, et al. Oral amoxicillin compared
with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with
fast breathing when referral is not possible: a randomised, open-label, equivalence trial. Lancet.
2015a;385(9979):1758-1766. doi:10.1016/S0140-6736(14)62285-6 [PubMed 25842223]
228. Tshefu A, Lokangaka A, African Neonatal Sepsis Trial (AFRINEST) group, et al. Simplified antibiotic regimens
compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young
infants with clinical signs of possible serious bacterial infection when referral is not possible: a randomised,
open-label, equivalence trial. Lancet. 2015b;385(9979):1767-1776. doi:10.1016/S0140-6736(14)62284-4
[PubMed 25842221]
229. Tu YH, Stiles ML, Allen LV Jr, et al. Stability of Amoxicillin Trihydrate-Potassium Clavulanate in Original
Containers and Unit Dose Oral Syringes. Am J Hosp Pharm. 1988;45(5):1092-1099. [PubMed 3400652]
230. US Department of Health and Human Services. National Heart, Lung, and Blood Institute (NHLBI). Evidence-
based management of sickle cell disease: expert panel report, 2014. https://www.nhlbi.nih.gov/health-
topics/evidence-based-management-sickle-cell-disease. Published 2014. Accessed January 3, 2023.
231. US Food and Drug Administration (FDA). Compounding certain beta-lactam products in shortage under
section 503A of the Federal Food Drug and Cosmetic Act. https://www.fda.gov/regulatory-
information/search-fda-guidance-documents/compounding-certain-beta-lactam-products-shortage-under-
section-503a-federal-food-drug-and-cosmetic. Published November 2022. Accessed January 3, 2023.
232. Valour F, Sénéchal A, Dupieux C, et al. Actinomycosis: etiology, clinical features, diagnosis, treatment, and
management. Infect Drug Resist. 2014;7:183-197. doi:10.2147/IDR.S39601 [PubMed 25045274]
233. Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. Clostridium difficile infection following systemic
antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. Int J
Antimicrob Agents. 2016;48(1):1-10. doi:10.1016/j.ijantimicag.2016.03.008 [PubMed 27216385]
234. Varela VM, Heller D, Silva-Senem MX, et al. Systemic Antimicrobials Adjunctive to a Repeated Mechanical
and Antiseptic Therapy for Aggressive Periodontitis: A 6-Month Randomized Controlled Trial. J Periodontol.
2011;82(8):1121-1130. [PubMed 21235333]
235. Wald ER, Applegate KE, Bordley C, et al. Clinical practice guideline for the diagnosis and management of
acute bacterial sinusitis in children aged 1 to 18 years. Pediatrics. 2013;132(1):e262-e280. [PubMed
23796742]
236. Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of
catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update.
Perit Dial Int. 2012;32(suppl 2):S32-S86. [PubMed 22851742]
237. Watson T, Hickok J, Fraker S, Korwek K, Poland RE, Septimus E. Evaluating the risk factors for hospital-onset
Clostridium difficile infections in a large healthcare system. Clin Infect Dis. 2018;66(12):1957-1959.
doi:10.1093/cid/cix1112 [PubMed 29272341]
238. Weingärtner L, Sitka U, Patsch R, Richter I. Experience with amoxycillin in neonates and premature babies.
Int J Clin Pharmacol Biopharm. 1977;15(4):184-188. [PubMed 870440]
239. Williams DJ, Creech CB, Walter EB, et al. Short- vs standard-course outpatient antibiotic therapy for
community-acquired pneumonia in children: the SCOUT-CAP randomized clinical trial. JAMA Pediatr.
2022;176(3):253-261. doi:10.1001/jamapediatrics.2021.5547 [PubMed 35040920]
240. Wilson KH. Prevention of anthrax. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.
http://www.uptodate.com. Accessed March 21, 2023.
241. Wilson WR, Gewitz M, Lockhart PB, et al; American Heart Association Young Hearts Rheumatic Fever,
Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and
Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; and the Council on Quality of
Care and Outcomes Research. Prevention of viridans group streptococcal infective endocarditis: a scientific
statement from the American Heart Association. Circulation. 2021;143(20):e963-e978.
doi:10.1161/CIR.0000000000000969 [PubMed 33853363]
242. Wilson W, Taubert KA, Gewitz M, et al; American Heart Association Rheumatic Fever, Endocarditis, and
Kawasaki Disease Committee; American Heart Association Council on Cardiovascular Disease in the Young;
American Heart Association Council on Clinical Cardiology; American Heart Association Council on
Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working
Group. Prevention of infective endocarditis. Guidelines from the American Heart Association: a guideline
from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee,
Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on
Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary
Working Group. Circulation. 2007;116(15):1736-1754. [PubMed 17446442]
243. Woods CR, Bradley JS, Chatterjee A, et al. Clinical practice guideline by the Pediatric Infectious Diseases
Society and the Infectious Diseases Society of America (PIDS/IDSA): 2021 guideline on diagnosis and
management of acute hematogenous osteomyelitis in pediatrics. J Pediatric Infect Dis Soc. 2021;10(8):801-
844. doi:10.1093/jpids/piab027 [PubMed 34350458]
244. World Health Organization (WHO). Mastitis: Causes and Management, Publication Number
WHO/FCH/CAH/00.13. World Health Organization: Geneva, Switzerland; 2000.
245. World Health Organization (WHO). WHO Model Prescribing Information: Drugs Used in Bacterial Infections.
Geneva, Switzerland: World Health Organization; 2001.
http://apps.who.int/medicinedocs/pdf/s5406e/s5406e.pdf. Accessed November 6, 2018.
246. World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in
the Eleventh WHO Model List of Essential Drugs. 2002.
http://www.who.int/maternal_child_adolescent/documents/55732/en/ [PubMed 23215911]
247. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021.
MMWR Recomm Rep. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1 [PubMed 34292926]
248. Wright AJ. The Penicillins. Mayo Clin Proc. 1999;74(3):290-307. [PubMed 10090000]
249. Wynn RL. Amoxicillin Update. Gen Dent. 1991;39(5):322,4,6. [PubMed 1812049]
250. Yang MS, Lee JY, Kim J, et al. Searching for the culprit drugs for Stevens-Johnson syndrome and toxic
epidermal necrolysis from a nationwide claim database in Korea. J Allergy Clin Immunol Pract.
2020;8(2):690-695.e2. doi:10.1016/j.jaip.2019.09.032 [PubMed 31614216]
251. Zareba-Szczudlik J, Romejko-Wolniewicz E, Lewandowski Z, et al. Evaluation of the amoxicillin

concentrations in amniotic fluid, placenta, umbilical cord blood and maternal serum two hours after oral
administration. Neuro Endocrinol Lett. 2017;38(7):502-508. [PubMed 29369602]
252. Zhan Y, Si M, Li M, Jiang Y. The risk of Helicobacter pylori infection for adverse pregnancy outcomes: a
systematic review and meta-analysis. Helicobacter. 2019;24(2):e12562. doi:10.1111/hel.12562 [PubMed
30672065]
253. Zhou H, Xu Q, Liu Y, Guo LT. Risk factors, incidence, and morbidity associated with antibiotic-associated
diarrhea in intensive care unit patients receiving antibiotic monotherapy. World J Clin Cases.
2020;8(10):1908-1915. doi:10.12998/wjcc.v8.i10.1908 [PubMed 32518780]
Topic 8673 Version 634.0

Amoxicillin - Drug Information - UpToDate

Uploaded by

Copyright:

Available Formats

You might also like

Amoxicillin - Drug Information - UpToDate

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Amoxicillin - Drug Information - UpToDate

Uploaded by

Copyright:

Available Formats

10/10/23, 15:48 Amoxicillin: Drug information - UpToDate

Brand Names: Canada

Usual dosage range: Oral: 500 mg to 1 g every 8 to 12 hours.

Actinomycosis (alternative agent) (off-label use):

Note: For initial therapy of mild infection or step-down therapy following

Oral: 500 mg 3 to 4 times daily or 1 g 3 times daily (Ref); higher doses of 4 to 6

Anthrax (alternative agent [susceptible strains only]) (off-label use):

Note: Consult public health officials for event-specific recommendations. A high

Inhalational (postexposure prophylaxis): Oral: 1 g every 8 hours (Ref); duration

Note: Anthrax vaccine should also be administered to exposed individuals

Cutaneous, without systemic involvement, treatment: Oral: 1 g every 8 hours;

Treatment of pulmonary exacerbations in patients without beta-lactamase-positive

Prevention of pulmonary exacerbations: Note: Reserve for patients with ≥3

Oral: 500 mg twice daily; dosing based on expert opinion (Ref).

Cervical infection in pregnancy due to Chlamydia trachomatis 

Cervical infection in pregnancy due to Chlamydia trachomatis (alternative

Endocarditis, prophylaxis before invasive dental procedures (off-label use):

Helicobacter pylori eradication 

Helicobacter pylori eradication: Oral:

Clarithromycin triple regimen: Amoxicillin 1 g twice daily in combination with

Concomitant regimen: Amoxicillin 1 g twice daily in combination with

Sequential regimen (alternative regimen): Amoxicillin 1 g twice daily plus a

Hybrid regimen (alternative regimen): Amoxicillin 1 g twice daily, plus a standard-

Levofloxacin triple regimen (salvage regimen): Amoxicillin 750 mg 3 times daily in

High-dose dual therapy (alternative salvage regimen): Amoxicillin 750 mg 4 times

Lyme disease (Borrelia spp. infection) (off-label use):

Erythema migrans: Oral: 500 mg 3 times daily for 14 days (Ref).

Otitis media, acute 

Otitis media, acute (alternative agent):

Note: Some experts recommend amoxicillin/clavulanate over amoxicillin alone

Periodontitis, severe, plaque-associated 

Periodontitis, severe, plaque-associated (off-label use): Oral: 500 mg every 8

Pneumococcal prophylaxis in patients at high risk 

Pneumococcal prophylaxis in patients at high risk (off-label use):

Oral: Dose not well-defined: 500 mg twice daily (Ref); based on

Note: For empiric therapy in outpatients without comorbidities or risk factors

Prosthetic joint infection, chronic suppression 

Prosthetic joint infection, chronic suppression (off-label use):

Note: For infection caused by beta-hemolytic streptococci, penicillin-susceptible

Oral: 500 mg 3 times daily (Ref); duration depends on patient-specific factors

Rhinosinusitis, acute bacterial 

Rhinosinusitis, acute bacterial:

Note: In uncomplicated acute bacterial rhinosinusitis, initial observation and

Skin and soft tissue infection 

Skin and soft tissue infection:

Erysipelas, treatment of mild infection or step-down therapy after initial parenteral

Erysipeloid (localized cutaneous Erysipelothrix rhusiopathiae infection):

Oral: 500 mg 3 times daily for 5 to 10 days (Ref).

Urinary tract infection 

Urinary tract infection:

Note: Not recommended for empiric therapy given decreased efficacy

Asymptomatic bacteriuria (≥105 CFU per mL) in pregnancy (eg, group B

Dosage adjustment for concomitant therapy: Significant drug interactions exist,

Dosing: Kidney Impairment: Adult

Altered kidney function:

Amoxicillin Dose Adjustments in Kidney Impairment

If the normal recommended If the normal recommended If the normal

No dosage adjustment No dosage adjustment No dosage adjustment